TitleAssociate Professor
InstitutionMD Anderson
DepartmentRadiation Physics
Address1400 Pressler St
Houston TX 77030-4008
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Chen GY, Cheng JC, Chen YF, Yang JC, Hsu FM. Circulating Exosomal Integrin ß3 Is Associated with Intracranial Failure and Survival in Lung Cancer Patients Receiving Cranial Irradiation for Brain Metastases: A Prospective Observational Study. Cancers (Basel). 2021 Jan 20; 13(3). PMID: 33498505.
    2. Cruz J, Garcia M, Garza C, DeLucia PR, Yang J. Object shape affects hand grip function for heavy objects in younger and older adults. Ergonomics. 2021 Jan 19; 1-11. PMID: 33325323.
      Citations:    Fields:    
    3. Hsu CC, Yang AY, Chen JY, Tsai HH, Lin SH, Tai PC, Huang MH, Hsu WH, Lin AM, Yang JC. Lysine Deprivation Induces AKT-AADAT Signaling and Overcomes EGFR-TKIs Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells. Cancers (Basel). 2021 Jan 13; 13(2). PMID: 33450879.
    4. Nazha B, Yang JC, Owonikoko TK. Benefits and limitations of real-world evidence: lessons from EGFR mutation-positive non-small-cell lung cancer. Future Oncol. 2021 Mar; 17(8):965-977. PMID: 33242257.
      Citations:    Fields:    
    5. Awad MM, Gadgeel SM, Borghaei H, Patnaik A, Yang JC, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Altan M, Jalal SI, Panwalkar A, Gubens M, Sequist LV, Saraf S, Zhao B, Piperdi B, Langer CJ. Long-Term Overall Survival From KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin With or Without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous NSCLC. J Thorac Oncol. 2021 Jan; 16(1):162-168. PMID: 33069888.
      Citations: 1     Fields:    
    6. Yu HA, Paz-Ares LG, Yang JC, Lee KH, Garrido P, Park K, Kim JH, Lee DH, Mao H, Wijayawardana SR, Gao L, Hozak RR, Chao BH, Planchard D. Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non-small Cell Lung Cancer. Clin Cancer Res. 2021 Feb 15; 27(4):992-1002. PMID: 33046516.
      Citations: 1     Fields:    
    7. Cappell KM, Sherry RM, Yang JC, Goff SL, Vanasse DA, McIntyre L, Rosenberg SA, Kochenderfer JN. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy. J Clin Oncol. 2020 Nov 10; 38(32):3805-3815. PMID: 33021872.
      Citations: 2     Fields:    
    8. Yang JC, Camidge DR, Yang CT, Zhou J, Guo R, Chiu CH, Chang GC, Shiah HS, Chen Y, Wang CC, Berz D, Su WC, Yang N, Wang Z, Fang J, Chen J, Nikolinakos P, Lu Y, Pan H, Maniam A, Bazhenova L, Shirai K, Jahanzeb M, Willis M, Masood N, Chowhan N, Hsia TC, Jian H, Lu S. Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 12; 15(12):1907-1918. PMID: 32916310.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    9. Lin YT, Yang JC, Chu CY. Esomeprazole-induced Stevens-Johnson syndrome in a patient who underwent nivolumab therapy for advanced lung adenocarcinoma. Lung Cancer. 2020 10; 148:177-178. PMID: 32933772.
      Citations:    Fields:    
    10. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Märten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: final analysis of the GioTag study. Future Oncol. 2020 Dec; 16(34):2799-2808. PMID: 32854536.
      Citations:    Fields:    
    11. Camidge DR, Kim HR, Ahn MJ, Yang JCH, Han JY, Hochmair MJ, Lee KH, Delmonte A, García Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira A, Gettinger SN, Tiseo M, Lin HM, Gupta N, Hanley MJ, Ni Q, Zhang P, Popat S. Brigatinib Versus Crizotinib in Advanced ALK Inhibitor-Naive ALK-Positive Non-Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial. J Clin Oncol. 2020 Nov 01; 38(31):3592-3603. PMID: 32780660.
      Citations: 6     Fields:    
    12. Wu SG, Yu CJ, Yang JC, Shih JY. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. Ther Adv Med Oncol. 2020; 12:1758835920946156. PMID: 32843903.
    13. Van Laethem F, Saba I, Lu J, Bhattacharya A, Tai X, Guinter TI, Engelhardt B, Alag A, Rojano M, Ashe JM, Hanada KI, Yang JC, Sun PD, Singer A. Novel MHC-Independent aßTCRs Specific for CD48, CD102, and CD155 Self-Proteins and Their Selection in the Thymus. Front Immunol. 2020; 11:1216. PMID: 32612609.
      Citations:    Fields:    
    14. Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csoszi T, Cheema PK, Rodriguez-Abreu D, Wollner M, Yang JC, Mazieres J, Orlandi FJ, Luft A, Gümüs M, Kato T, Kalemkerian GP, Luo Y, Ebiana V, Pietanza MC, Kim HR. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020 07 20; 38(21):2369-2379. PMID: 32468956.
      Citations: 11     Fields:    
    15. Paik PK, Felip E, Veillon R, Sakai H, Cortot AB, Garassino MC, Mazieres J, Viteri S, Senellart H, Van Meerbeeck J, Raskin J, Reinmuth N, Conte P, Kowalski D, Cho BC, Patel JD, Horn L, Griesinger F, Han JY, Kim YC, Chang GC, Tsai CL, Yang JC, Chen YM, Smit EF, van der Wekken AJ, Kato T, Juraeva D, Stroh C, Bruns R, Straub J, Johne A, Scheele J, Heymach JV, Le X. Tepotinib in Non-Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations. N Engl J Med. 2020 09 03; 383(10):931-943. PMID: 32469185.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    16. Wu YL, Cheng Y, Zhou J, Lu S, Zhang Y, Zhao J, Kim DW, Soo RA, Kim SW, Pan H, Chen YM, Chian CF, Liu X, Tan DSW, Bruns R, Straub J, Johne A, Scheele J, Park K, Yang JC. Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial. Lancet Respir Med. 2020 11; 8(11):1132-1143. PMID: 32479794.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    17. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Liu YN, Su KY, Chang YL, Wu CT, Liao BC, Hsu CC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving Crizotinib. Oncologist. 2020 08; 25(8):702-711. PMID: 32386255.
      Citations: 1     Fields:    
    18. Rakshit R, Xiang Y, Yang J. Dynamic-joint-strength-based two-dimensional symmetric maximum weight-lifting simulation: Model development and validation. Proc Inst Mech Eng H. 2020 Jul; 234(7):660-673. PMID: 32267824.
      Citations:    Fields:    
    19. Hung PS, Huang MH, Kuo YY, Yang JC. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer. Cancers (Basel). 2020 Mar 31; 12(4). PMID: 32244355.
    20. Yang WC, Hsu FM, Chen YH, Shih JY, Yu CJ, Lin ZZ, Lu SH, Yang JC, Cheng AL, Kuo SH. Clinical outcomes and toxicity predictors of thoracic re-irradiation for locoregionally recurrent lung cancer. Clin Transl Radiat Oncol. 2020 May; 22:76-82. PMID: 32280792.
    21. de Bono J, Lin CC, Chen LT, Corral J, Michalarea V, Rihawi K, Ong M, Lee JH, Hsu CH, Yang JC, Shiah HS, Yen CJ, Anthoney A, Jove M, Buschke S, Fuertig R, Schmid U, Goeldner RG, Strelkowa N, Huang DC, Bogenrieder T, Twelves C, Cheng AL. Two first-in-human studies of xentuzumab, a humanised insulin-like growth factor (IGF)-neutralising antibody, in patients with advanced solid tumours. Br J Cancer. 2020 04; 122(9):1324-1332. PMID: 32161368.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    22. Sequist LV, Han JY, Ahn MJ, Cho BC, Yu H, Kim SW, Yang JC, Lee JS, Su WC, Kowalski D, Orlov S, Cantarini M, Verheijen RB, Mellemgaard A, Ottesen L, Frewer P, Ou X, Oxnard G. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020 03; 21(3):373-386. PMID: 32027846.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    23. Yang CY, Yang JC, Yang PC. Precision Management of Advanced Non-Small Cell Lung Cancer. Annu Rev Med. 2020 01 27; 71:117-136. PMID: 31986082.
      Citations: 2     Fields:    Translation:Humans
    24. Tan DS, Leighl NB, Riely GJ, Yang JC, Sequist LV, Wolf J, Seto T, Felip E, Aix SP, Jonnaert M, Pan C, Tan EY, Ko J, Moody SE, Kim DW. Safety and efficacy of nazartinib (EGF816) in adults with EGFR-mutant non-small-cell lung carcinoma: a multicentre, open-label, phase 1 study. Lancet Respir Med. 2020 06; 8(6):561-572. PMID: 31954624.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    25. Yang JC, Schuler M, Popat S, Miura S, Heeke S, Park K, Märten A, Kim ES. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. J Thorac Oncol. 2020 05; 15(5):803-815. PMID: 31931137.
      Citations: 11     Fields:    
    26. Baus J, Harry JR, Yang J. Jump and Landing Biomechanical Variables and Methods: A Literature Review. Crit Rev Biomed Eng. 2020; 48(4):211-222. PMID: 33463958.
      Citations:    Fields:    
    27. Yang JCH, Kim SW, Kim DW, Lee JS, Cho BC, Ahn JS, Lee DH, Kim TM, Goldman JW, Natale RB, Brown AP, Collins B, Chmielecki J, Vishwanathan K, Mendoza-Naranjo A, Ahn MJ. Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study. J Clin Oncol. 2020 02 20; 38(6):538-547. PMID: 31809241.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    28. Liao BC, Griesing S, Yang JC. Second-line treatment of EGFR T790M-negative non-small cell lung cancer patients. Ther Adv Med Oncol. 2019; 11:1758835919890286. PMID: 31803256.
    29. Yang CY, Liao WY, Ho CC, Chen KY, Tsai TH, Hsu CL, Su KY, Chang YL, Wu CT, Hsu CC, Liao BC, Hsu WH, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors. Eur J Cancer. 2020 01; 124:110-122. PMID: 31760310.
      Citations: 6     Fields:    Translation:Humans
    30. Tan WL, Chua KLM, Lin CC, Lee VHF, Tho LM, Chan AW, Ho GF, Reungwetwattana T, Yang JC, Kim DW, Soo RA, Ahn YC, Onishi H, Ahn MJ, Mok TSK, Tan DSW, Yang F. Asian Thoracic Oncology Research Group Expert Consensus Statement on Optimal Management of Stage III NSCLC. J Thorac Oncol. 2020 03; 15(3):324-343. PMID: 31733357.
      Citations: 2     Fields:    
    31. Gadgeel S, Shaw AT, Barlesi F, Crino L, Yang JC, Dingemans AM, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Smoljanovic V, Ou SI. Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies. Lung Cancer (Auckl). 2019; 10:125-130. PMID: 32009824.
    32. Gros A, Tran E, Parkhurst MR, Ilyas S, Pasetto A, Groh EM, Robbins PF, Yossef R, Garcia-Garijo A, Fajardo CA, Prickett TD, Jia L, Gartner JJ, Ray S, Ngo L, Wunderllich JR, Yang JC, Rosenberg SA. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. J Clin Invest. 2019 11 01; 129(11):4992-5004. PMID: 31609250.
      Citations: 14     Fields:    Translation:HumansCells
    33. Yun MR, Choi HM, Lee YW, Joo HS, Park CW, Choi JW, Kim DH, Kang HN, Pyo KH, Shin EJ, Shim HS, Soo RA, Yang JC, Lee SS, Chang H, Kim MH, Hong MH, Kim HR, Cho BC. Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK-rearranged lung cancer. EMBO Mol Med. 2019 12; 11(12):e10581. PMID: 31633304.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    34. Ou SI, Gadgeel SM, Barlesi F, Yang JC, De Petris L, Kim DW, Govindan R, Dingemans AM, Crino L, Léna H, Popat S, Ahn JS, Dansin E, Mitry E, Müller B, Bordogna W, Balas B, Morcos PN, Shaw AT. Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer. Lung Cancer. 2020 01; 139:22-27. PMID: 31706099.
      Citations: 1     Fields:    
    35. Yang JC, Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Hozak RR, Nguyen TS, Zhang WL, Enatsu S, Puri T, Orlando M. A Randomized Phase 2 Study of Gefitinib With or Without Pemetrexed as First-line Treatment in Nonsquamous NSCLC With EGFR Mutation: Final Overall Survival and Biomarker Analysis. J Thorac Oncol. 2020 01; 15(1):91-100. PMID: 31605797.
      Citations: 1     Fields:    
    36. Lee KWC, Lord SJ, Kasherman L, Marschner I, Stockler M, Gralla R, Yang JC, Mok T, Lee CK. The impact of smoking on the effectiveness of immune checkpoint inhibitors - a systematic review and meta-analysis. Acta Oncol. 2020 Jan; 59(1):96-100. PMID: 31552770.
      Citations:    Fields:    Translation:Humans
    37. Hsu CC, Liao BC, Liao WY, Markovets A, Stetson D, Thress K, Yang JC. Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2020 01; 15(1):50-61. PMID: 31557536.
      Citations: 7     Fields:    
    38. Chatani PD, Yang JC. Mutated RAS: Targeting the "Untargetable" with T Cells. Clin Cancer Res. 2020 02 01; 26(3):537-544. PMID: 31511296.
      Citations: 3     Fields:    Translation:HumansCells
    39. Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA, Huang J. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun. 2019 09 05; 10(1):4016. PMID: 31488817.
      Citations: 15     Fields:    Translation:HumansAnimalsCells
    40. Hong ST, Lin H, Wang CS, Chang CH, Lin AM, Yang JC, Lo YL. Improving the anticancer effect of afatinib and microRNA by using lipid polymeric nanoparticles conjugated with dual pH-responsive and targeting peptides. J Nanobiotechnology. 2019 Aug 19; 17(1):89. PMID: 31426807.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    41. Doran SL, Stevanovic S, Adhikary S, Gartner JJ, Jia L, Kwong MLM, Faquin WC, Hewitt SM, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. T-Cell Receptor Gene Therapy for Human Papillomavirus-Associated Epithelial Cancers: A First-in-Human, Phase I/II Study. J Clin Oncol. 2019 10 20; 37(30):2759-2768. PMID: 31408414.
      Citations: 11     Fields:    Translation:HumansCellsCTClinical Trials
    42. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Märten A, Cufer T. Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study. Future Oncol. 2019 Sep; 15(25):2905-2914. PMID: 31370698.
      Citations: 9     Fields:    Translation:Humans
    43. Ahn MJ, Han JY, Kim DW, Cho BC, Kang JH, Kim SW, Yang JC, Mitsudomi T, Lee JS. Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies. Cancer Res Treat. 2020 Jan; 52(1):284-291. PMID: 31345012.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    44. Wu TH, Hsiue EH, Yang JC. Opportunities of circulating tumor DNA in lung cancer. Cancer Treat Rev. 2019 Aug; 78:31-41. PMID: 31326635.
      Citations: 1     Fields:    Translation:Humans
    45. Yao ZH, Liao WY, Ho CC, Chen KY, Shih JY, Chen JS, Lin ZZ, Lin CC, Yang JC, Yu CJ. Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients. Eur J Cancer. 2019 08; 117:107-115. PMID: 31279301.
      Citations: 3     Fields:    Translation:HumansCells
    46. Woodford R, Loh Y, Lee J, Cooper W, Marschner I, Lewis CR, Millward M, Lord S, Gralla RJ, Yang JC, Mok T, Lee CK. Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer. Future Oncol. 2019 Jul; 15(20):2371-2383. PMID: 31354046.
      Citations:    Fields:    Translation:Humans
    47. Lee JH, Chen HY, Hsu FM, Chen JS, Liao WY, Shih JY, Yu CJ, Chen KY, Tsai TH, Yang JC. Cranial Irradiation for Patients with Epidermal Growth Factor Receptor (EGFR) Mutant Lung Cancer Who Have Brain Metastases in the Era of a New Generation of EGFR Inhibitors. Oncologist. 2019 12; 24(12):e1417-e1425. PMID: 31127020.
      Citations: 2     Fields:    Translation:Humans
    48. Liang SK, Ko JC, Yang JC, Shih JY. Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations. Lung Cancer. 2019 07; 133:103-109. PMID: 31200815.
      Citations: 3     Fields:    Translation:Humans
    49. Goff SL, Morgan RA, Yang JC, Sherry RM, Robbins PF, Restifo NP, Feldman SA, Lu YC, Lu L, Zheng Z, Xi L, Epstein M, McIntyre LS, Malekzadeh P, Raffeld M, Fine HA, Rosenberg SA. Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor-transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma. J Immunother. 2019 05; 42(4):126-135. PMID: 30882547.
      Citations: 21     Fields:    Translation:HumansCells
    50. Chumacero EA, Yang J. Basin of Attraction and Limit Cycle Amplitude of an Ankle-Hip Model of Balance on a Balance Board. J Biomech Eng. 2019 Apr 24. PMID: 31017633.
      Citations:    Fields:    
    51. Park K, Wan-Teck Lim D, Okamoto I, Yang JC. First-line afatinib for the treatment of EGFR mutation-positive non-small-cell lung cancer in the 'real-world' clinical setting. Ther Adv Med Oncol. 2019; 11:1758835919836374. PMID: 31019567.
    52. Jafferji MS, Yang JC. Adoptive T-Cell Therapy for Solid Malignancies. Surg Oncol Clin N Am. 2019 07; 28(3):465-479. PMID: 31079800.
      Citations: 1     Fields:    Translation:HumansAnimals
    53. Park K, Bennouna J, Boyer M, Hida T, Hirsh V, Kato T, Lu S, Mok T, Nakagawa K, O'Byrne K, Paz-Ares L, Schuler M, Sibilot DM, Tan EH, Tanaka H, Wu YL, Yang JC, Zhang L, Zhou C, Märten A, Tang W, Yamamoto N. Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. Lung Cancer. 2019 06; 132:126-131. PMID: 31097085.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    54. Schuler M, Paz-Ares L, Sequist LV, Hirsh V, Lee KH, Wu YL, Lu S, Zhou C, Feng J, Ellis SH, Samuelsen CH, Tang W, Märten A, Ehrnrooth E, Park K, Yang JC. First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Lung Cancer. 2019 07; 133:10-19. PMID: 31200814.
      Citations:    Fields:    Translation:HumansCTClinical Trials
    55. Yang JC. Bevacizumab in EGFR-positive NSCLC: time to change first-line treatment? Lancet Oncol. 2019 05; 20(5):602-603. PMID: 30975629.
      Citations:    Fields:    Translation:Humans
    56. Xu M, Yang J, Lieberman IH, Haddas R. Finite element method-based study of pedicle screw-bone connection in pullout test and physiological spinal loads. Med Eng Phys. 2019 05; 67:11-21. PMID: 30879945.
      Citations: 1     Fields:    
    57. Hsiue EH, Lee PL, Chen YH, Wu TH, Cheng CF, Cheng KM, Yang PC, Chen HW, Lin PY, Chiang DL, Wu HD, Yang JC, Yu CJ. Weaning outcome of solid cancer patients requiring mechanical ventilation in the intensive care unit. J Formos Med Assoc. 2019 Jun; 118(6):995-1004. PMID: 30857753.
      Citations:    Fields:    Translation:Humans
    58. Lee JH, Chen TW, Hsu CH, Yen YH, Yang JC, Cheng AL, Sasaki SI, Chiu LL, Sugihara M, Ishizuka T, Oguma T, Tajima N, Lin CC. A phase I study of pexidartinib, a colony-stimulating factor 1 receptor inhibitor, in Asian patients with advanced solid tumors. Invest New Drugs. 2020 02; 38(1):99-110. PMID: 30825104.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    59. Schuler M, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Massey D, Märten A, Paz-Ares L, Park K. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression. J Cancer Res Clin Oncol. 2019 Jun; 145(6):1569-1579. PMID: 30783814.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    60. Yang JC, Shepherd FA, Kim DW, Lee GW, Lee JS, Chang GC, Lee SS, Wei YF, Lee YG, Laus G, Collins B, Pisetzky F, Horn L. Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M-Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report. J Thorac Oncol. 2019 05; 14(5):933-939. PMID: 30763730.
      Citations: 16     Fields:    Translation:Humans
    61. Doi T, Yang JC, Shitara K, Naito Y, Cheng AL, Sarashina A, Pronk LC, Takeuchi Y, Lin CC. Phase I Study of the Focal Adhesion Kinase Inhibitor BI 853520 in Japanese and Taiwanese Patients with Advanced or Metastatic Solid Tumors. Target Oncol. 2019 02; 14(1):57-65. PMID: 30725402.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    62. Lin YT, Chen JS, Liao WY, Ho CC, Hsu CL, Yang CY, Chen KY, Lee JH, Lin ZZ, Shih JY, Yang JC, Yu CJ. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations. Int J Cancer. 2019 06 01; 144(11):2887-2896. PMID: 30485437.
      Citations: 5     Fields:    Translation:Humans
    63. Barros AO, Yang J. A Review of Magnetically Actuated Milli/Micro-Scale Robots Locomotion and Features. Crit Rev Biomed Eng. 2019; 47(5):379-394. PMID: 32422028.
      Citations: 1     Fields:    
    64. Stevanovic S, Helman SR, Wunderlich JR, Langhan MM, Doran SL, Kwong MLM, Somerville RPT, Klebanoff CA, Kammula US, Sherry RM, Yang JC, Rosenberg SA, Hinrichs CS. A Phase II Study of Tumor-infiltrating Lymphocyte Therapy for Human Papillomavirus-associated Epithelial Cancers. Clin Cancer Res. 2019 03 01; 25(5):1486-1493. PMID: 30518633.
      Citations: 14     Fields:    Translation:HumansCellsCTClinical Trials
    65. Yang JC, Gadgeel SM, Sequist LV, Wu CL, Papadimitrakopoulou VA, Su WC, Fiore J, Saraf S, Raftopoulos H, Patnaik A. Pembrolizumab in Combination With Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC With Sensitizing EGFR Mutation. J Thorac Oncol. 2019 03; 14(3):553-559. PMID: 30529597.
      Citations: 16     Fields:    Translation:HumansCTClinical Trials
    66. Ahn MJ, Tsai CM, Shepherd FA, Bazhenova L, Sequist LV, Hida T, Yang JCH, Ramalingam SS, Mitsudomi T, Jänne PA, Mann H, Cantarini M, Goss G. Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies. Cancer. 2019 03 15; 125(6):892-901. PMID: 30512189.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    67. Yang Q, Li H, Shen S, Zhang G, Huang R, Feng Y, Yang J, Ma S. Study of the micro-climate and bacterial distribution in the deadspace of N95 filtering face respirators. Sci Rep. 2018 11 26; 8(1):17382. PMID: 30478258.
      Citations: 1     Fields:    Translation:HumansCellsPHPublic Health
    68. Xu M, Yang J, Lieberman I, Haddas R. Stress distribution in vertebral bone and pedicle screw and screw-bone load transfers among various fixation methods for lumbar spine surgical alignment: A finite element study. Med Eng Phys. 2019 01; 63:26-32. PMID: 30344069.
      Citations: 2     Fields:    Translation:Humans
    69. Hochmair MJ, Morabito A, Hao D, Yang CT, Soo RA, Yang JC, Gucalp R, Halmos B, Wang L, Golembesky A, Märten A, Cufer T. Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study. Future Oncol. 2018 Nov; 14(27):2861-2874. PMID: 30336693.
      Citations: 14     Fields:    Translation:Humans
    70. Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Lee JS, Hochmair MJ, Li JY, Chang GC, Lee KH, Gridelli C, Delmonte A, Garcia Campelo R, Kim DW, Bearz A, Griesinger F, Morabito A, Felip E, Califano R, Ghosh S, Spira A, Gettinger SN, Tiseo M, Gupta N, Haney J, Kerstein D, Popat S. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018 11 22; 379(21):2027-2039. PMID: 30280657.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    71. Wu YL, Zhang L, Kim DW, Liu X, Lee DH, Yang JC, Ahn MJ, Vansteenkiste JF, Su WC, Felip E, Chia V, Glaser S, Pultar P, Zhao S, Peng B, Akimov M, Tan DSW. Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 11 01; 36(31):3101-3109. PMID: 30156984.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    72. Gadgeel SM, Stevenson JP, Langer CJ, Gandhi L, Borghaei H, Patnaik A, Villaruz LC, Gubens M, Hauke R, Yang JC, Sequist LV, Bachman R, Saraf S, Raftopoulos H, Papadimitrakopoulou V. Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. Lung Cancer. 2018 11; 125:273-281. PMID: 30429032.
      Citations: 19     Fields:    Translation:Humans
    73. Borghaei H, Langer CJ, Gadgeel S, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Saraf S, Keller SM, Gandhi L. 24-Month Overall Survival from KEYNOTE-021 Cohort G: Pemetrexed and Carboplatin with or without Pembrolizumab as First-Line Therapy for Advanced Nonsquamous Non-Small Cell Lung Cancer. J Thorac Oncol. 2019 01; 14(1):124-129. PMID: 30138764.
      Citations: 52     Fields:    Translation:Humans
    74. Wu SG, Liu YN, Yu CJ, Yang JC, Shih JY. Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion. Genes Chromosomes Cancer. 2018 10; 57(10):513-521. PMID: 30107055.
      Citations: 3     Fields:    Translation:Humans
    75. Murakami H, Nokihara H, Hayashi H, Seto T, Park K, Azuma K, Tsai CM, Yang JC, Nishio M, Kim SW, Kiura K, Inoue A, Takeda K, Kang JH, Nakagawa T, Takeda K, Akazawa R, Kaneko Y, Shimazaki M, Morita S, Fukuoka M, Nakagawa K. Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations. Cancer Sci. 2018 Sep; 109(9):2852-2862. PMID: 29972716.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    76. Peters S, Curioni-Fontecedro A, Nechushtan H, Shih JY, Liao WY, Gautschi O, Spataro V, Unk M, Yang JC, Lorence RM, Carrière P, Cseh A, Chang GC. Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program. J Thorac Oncol. 2018 12; 13(12):1897-1905. PMID: 30096481.
      Citations: 16     Fields:    Translation:Humans
    77. Gebski V, Yang JC, Lee CK. Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply. JAMA Oncol. 2018 08 01; 4(8):1138-1139. PMID: 29931217.
      Citations: 1     Fields:    Translation:Humans
    78. Mehta GU, Malekzadeh P, Shelton T, White DE, Butman JA, Yang JC, Kammula US, Goff SL, Rosenberg SA, Sherry RM. Outcomes of Adoptive Cell Transfer With Tumor-infiltrating Lymphocytes for Metastatic Melanoma Patients With and Without Brain Metastases. J Immunother. 2018 Jun; 41(5):241-247. PMID: 29672342.
      Citations: 4     Fields:    Translation:HumansCells
    79. Chumacero E, Yang J, Chagdes JR. Effect of sensory-motor latencies and active muscular stiffness on stability for an ankle-hip model of balance on a balance board. J Biomech. 2018 06 25; 75:77-88. PMID: 29861093.
      Citations:    Fields:    Translation:Humans
    80. Liao BC, Lin CC, Yang JC. Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials? Expert Opin Pharmacother. 2018 06; 19(8):851-864. PMID: 29726292.
      Citations: 2     Fields:    Translation:Humans
    81. Wu TH, Lee LJ, Yuan CT, Chen TW, Yang JC. Prognostic factors and treatment outcomes of malignant pleural mesothelioma in Eastern Asian patients - A Taiwanese study. J Formos Med Assoc. 2019 Jan; 118(1 Pt 2):230-236. PMID: 29709339.
      Citations: 1     Fields:    Translation:Humans
    82. Lin SY, Yang CY, Liao BC, Ho CC, Liao WY, Chen KY, Tsai TH, Hsu CL, Hsu WH, Su KY, Chang YL, Lee JH, Lin CC, Shih JY, Yang JC, Yu CJ. Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. J Cancer. 2018; 9(10):1813-1820. PMID: 29805708.
    83. Yun MR, Lim SM, Kim SK, Choi HM, Pyo KH, Kim SK, Lee JM, Lee YW, Choi JW, Kim HR, Hong MH, Haam K, Huh N, Kim JH, Kim YS, Shim HS, Soo RA, Shih JY, Yang JC, Kim M, Cho BC. Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. Cancer Res. 2018 06 15; 78(12):3350-3362. PMID: 29669761.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    84. Yan Y, Yang J, Beddar S, Ibbott G, Wen Z, Court LE, Hwang KP, Kadbi M, Krishnan S, Fuller CD, Frank SJ, Yang J, Balter P, Kudchadker RJ, Wang J. A methodology to investigate the impact of image distortions on the radiation dose when using magnetic resonance images for planning. Phys Med Biol. 2018 04 05; 63(8):085005. PMID: 29528037.
      Citations: 4     Fields:    Translation:Humans
    85. Wu TH, Yang JC. Real-World or Controlled Clinical Trial Data in Real-World Practice. J Thorac Oncol. 2018 04; 13(4):470-472. PMID: 29576285.
      Citations: 1     Fields:    Translation:Humans
    86. Mann H, Andersohn F, Bodnar C, Mitsudomi T, Mok TSK, Yang JC, Hoyle C. Adjusted Indirect Comparison Using Propensity Score Matching of Osimertinib to Platinum-Based Doublet Chemotherapy in Patients with EGFRm T790M NSCLC Who Have Progressed after EGFR-TKI. Clin Drug Investig. 2018 Apr; 38(4):319-331. PMID: 29247383.
      Citations: 4     Fields:    Translation:Humans
    87. Wu YL, Yang JC, Kim DW, Lu S, Zhou J, Seto T, Yang JJ, Yamamoto N, Ahn MJ, Takahashi T, Yamanaka T, Kemner A, Roychowdhury D, Paolini J, Usari T, Wilner KD, Goto K. Phase II Study of Crizotinib in East Asian Patients With ROS1-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 05 10; 36(14):1405-1411. PMID: 29596029.
      Citations: 43     Fields:    Translation:HumansCTClinical Trials
    88. Lee CK, Lord S, Marschner I, Wu YL, Sequist L, Rosell R, Fukuoka M, Mitsudomi T, Asher R, Davies L, Gebski V, Gralla R, Mok T, Yang JC. The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer. J Thorac Oncol. 2018 06; 13(6):792-800. PMID: 29580950.
      Citations: 1     Fields:    Translation:Humans
    89. Lee CK, Man J, Lord S, Cooper W, Links M, Gebski V, Herbst RS, Gralla RJ, Mok T, Yang JC. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Feb 01; 4(2):210-216. PMID: 29270615.
      Citations: 73     Fields:    Translation:Humans
    90. Wu TH, Hsiue EH, Lee JH, Lin CC, Liao WY, Ho CC, Shih JY, Yu CJ, Yang JC. Best Response According to RECIST During First-line EGFR-TKI Treatment Predicts Survival in EGFR Mutation-positive Non-Small-cell Lung Cancer Patients. Clin Lung Cancer. 2018 05; 19(3):e361-e372. PMID: 29477365.
      Citations: 1     Fields:    Translation:Humans
    91. Wu YL, Hirsh V, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Schuler M, Mok T, Yamamoto N, O'Byrne K, Geater SL, Zhou C, Massey D, Märten A, Lungershausen J, Yang JC. Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). Patient. 2018 02; 11(1):131-141. PMID: 29178024.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    92. Jin L, Ge H, Long Y, Yang C, Chang YE, Mu L, Sayour EJ, De Leon G, Wang QJ, Yang JC, Kubilis PS, Bao H, Xia S, Lu D, Kong Y, Hu L, Shang Y, Jiang C, Nie J, Li S, Gu Y, Sun J, Mitchell DA, Lin Z, Huang J. CD70, a novel target of CAR T-cell therapy for gliomas. Neuro Oncol. 2018 01 10; 20(1):55-65. PMID: 28651374.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    93. Lin CC, Shih JY, Yu CJ, Ho CC, Liao WY, Lee JH, Tsai TH, Su KY, Hsieh MS, Chang YL, Bai YY, Huang DD, Thress KS, Yang JC. Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study. Lancet Respir Med. 2018 02; 6(2):107-116. PMID: 29249325.
      Citations: 22     Fields:    Translation:Humans
    94. Gadgeel S, Shaw AT, Barlesi F, Crinò L, Yang JC, Dingemans AC, Kim DW, de Marinis F, Schulz M, Liu S, Gupta R, Kotb A, Ou SI. Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC. Br J Cancer. 2018 01; 118(1):38-42. PMID: 29149104.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    95. Nilsson MB, Sun H, Diao L, Tong P, Liu D, Li L, Fan Y, Poteete A, Lim SO, Howells K, Haddad V, Gomez D, Tran H, Pena GA, Sequist LV, Yang JC, Wang J, Kim ES, Herbst R, Lee JJ, Hong WK, Wistuba I, Hung MC, Sood AK, Heymach JV. Stress hormones promote EGFR inhibitor resistance in NSCLC: Implications for combinations with ß-blockers. Sci Transl Med. 2017 Nov 08; 9(415). PMID: 29118262.
      Citations: 23     Fields:    Translation:HumansCells
    96. Yang WC, Xiao F, Shih JY, Ho CC, Chen YF, Tseng HM, Chen KY, Liao WY, Yu CJ, Yang JC, Kuo SH, Cheng JC, Yang PC, Hsu FM. Epidermal growth factor receptor mutation predicts favorable outcomes in non-small cell lung cancer patients with brain metastases treated with stereotactic radiosurgery. Radiother Oncol. 2018 Feb; 126(2):368-374. PMID: 29111173.
      Citations: 4     Fields:    Translation:Humans
    97. Ahn MJ, Kim DW, Cho BC, Kim SW, Lee JS, Ahn JS, Kim TM, Lin CC, Kim HR, John T, Kao S, Goldman JW, Su WC, Natale R, Rabbie S, Harrop B, Overend P, Yang Z, Yang JC. Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. Lancet Respir Med. 2017 11; 5(11):891-902. PMID: 29056570.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    98. Mok TSK, Kim SW, Wu YL, Nakagawa K, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Shi X, Rukazenkov Y, Haddad V, Thress KS, Soria JC. Gefitinib Plus Chemotherapy Versus Chemotherapy in Epidermal Growth Factor Receptor Mutation-Positive Non-Small-Cell Lung Cancer Resistant to First-Line Gefitinib (IMPRESS): Overall Survival and Biomarker Analyses. J Clin Oncol. 2017 Dec 20; 35(36):4027-4034. PMID: 28968167.
      Citations: 28     Fields:    Translation:Humans
    99. Kubota K, Yoshioka H, Oshita F, Hida T, Yoh K, Hayashi H, Kato T, Kaneda H, Yamada K, Tanaka H, Ichinose Y, Park K, Cho EK, Lee KH, Lin CB, Yang JC, Hara K, Asato T, Nakagawa K. Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2017 Nov 10; 35(32):3662-3670. PMID: 28902534.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    100. Ramalingam SS, Yang JC, Lee CK, Kurata T, Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, Ghiorghiu S, Stetson D, Markovets A, Barrett JC, Thress KS, Jänne PA. Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018 03 20; 36(9):841-849. PMID: 28841389.
      Citations: 88     Fields:    Translation:HumansCTClinical Trials
    101. Lu YC, Parker LL, Lu T, Zheng Z, Toomey MA, White DE, Yao X, Li YF, Robbins PF, Feldman SA, van der Bruggen P, Klebanoff CA, Goff SL, Sherry RM, Kammula US, Yang JC, Rosenberg SA. Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. J Clin Oncol. 2017 Oct 10; 35(29):3322-3329. PMID: 28809608.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    102. Thress KS, Jacobs V, Angell HK, Yang JC, Sequist LV, Blackhall F, Su WC, Schuler M, Wolf J, Gold KA, Cantarini M, Barrett JC, Jänne PA. Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial. J Thorac Oncol. 2017 10; 12(10):1588-1594. PMID: 28751247.
      Citations: 6     Fields:    Translation:HumansCTClinical Trials
    103. Kochenderfer JN, Somerville RPT, Lu T, Yang JC, Sherry RM, Feldman SA, McIntyre L, Bot A, Rossi J, Lam N, Rosenberg SA. Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy. Mol Ther. 2017 10 04; 25(10):2245-2253. PMID: 28803861.
      Citations: 66     Fields:    Translation:HumansCells
    104. Gandhi L, Ou SI, Shaw AT, Barlesi F, Dingemans AC, Kim DW, Camidge DR, Hughes BGM, Yang JC, de Castro J, Crino L, Léna H, Do P, Golding S, Bordogna W, Zeaiter A, Kotb A, Gadgeel S. Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria. Eur J Cancer. 2017 09; 82:27-33. PMID: 28646771.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    105. Yang JC, Ou SI, De Petris L, Gadgeel S, Gandhi L, Kim DW, Barlesi F, Govindan R, Dingemans AC, Crino L, Lena H, Popat S, Ahn JS, Dansin E, Golding S, Bordogna W, Balas B, Morcos PN, Zeaiter A, Shaw AT. Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 10; 12(10):1552-1560. PMID: 28689043.
      Citations: 22     Fields:    Translation:HumansCTClinical Trials
    106. Yang JC, Mok T, Han B, Orlando M, Puri T, Park K. A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2018 01; 19(1):27-34. PMID: 28743421.
      Citations: 5     Fields:    Translation:Humans
    107. Mahajan A, Ahmed S, McAleer MF, Weinberg JS, Li J, Brown P, Settle S, Prabhu SS, Lang FF, Levine N, McGovern S, Sulman E, McCutcheon IE, Azeem S, Cahill D, Tatsui C, Heimberger AB, Ferguson S, Ghia A, Demonte F, Raza S, Guha-Thakurta N, Yang J, Sawaya R, Hess KR, Rao G. Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. Lancet Oncol. 2017 08; 18(8):1040-1048. PMID: 28687375.
      Citations: 82     Fields:    Translation:HumansCTClinical Trials
    108. Soh SX, Siddiqui FJ, Allen JC, Kim GW, Lee JC, Yatabe Y, Soda M, Mano H, Soo RA, Chin TM, Ebi H, Yano S, Matsuo K, Niu X, Lu S, Isobe K, Lee JH, Yang JC, Zhao M, Zhou C, Lee JK, Lee SH, Lee JY, Ahn MJ, Tan TJ, Tan DS, Tan EH, Ong ST, Lim WT. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. Oncotarget. 2017 Jun 20; 8(25):41474-41486. PMID: 28467813.
      Citations: 4     Fields:    Translation:Humans
    109. Lee CK, Davies L, Wu YL, Mitsudomi T, Inoue A, Rosell R, Zhou C, Nakagawa K, Thongprasert S, Fukuoka M, Lord S, Marschner I, Tu YK, Gralla RJ, Gebski V, Mok T, Yang JC. Gefitinib or Erlotinib vs Chemotherapy for EGFR Mutation-Positive Lung Cancer: Individual Patient Data Meta-Analysis of Overall Survival. J Natl Cancer Inst. 2017 06 01; 109(6). PMID: 28376144.
      Citations: 30     Fields:    Translation:HumansCells
    110. Chen D, Yang J. Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies. Transl Res. 2017 09; 187:11-21. PMID: 28641074.
      Citations: 5     Fields:    Translation:HumansCells
    111. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      Citations: 15     Fields:    Translation:Humans
    112. Jenkins S, Yang JC, Jänne PA, Thress KS, Yu K, Hodge R, Weston S, Dearden S, Patel S, Cantarini M, Shepherd FA. EGFR Mutation Analysis for Prospective Patient Selection in Two Phase II Registration Studies of Osimertinib. J Thorac Oncol. 2017 08; 12(8):1247-1256. PMID: 28527899.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    113. Liao BC, Lin CC, Lee JH, Yang JC. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017 08; 110:7-13. PMID: 28676222.
      Citations: 11     Fields:    Translation:Humans
    114. Jenkins S, Yang JC, Ramalingam SS, Yu K, Patel S, Weston S, Hodge R, Cantarini M, Jänne PA, Mitsudomi T, Goss GD. Plasma ctDNA Analysis for Detection of the EGFR T790M Mutation in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 07; 12(7):1061-1070. PMID: 28428148.
      Citations: 54     Fields:    Translation:Humans
    115. Chandran SS, Somerville RPT, Yang JC, Sherry RM, Klebanoff CA, Goff SL, Wunderlich JR, Danforth DN, Zlott D, Paria BC, Sabesan AC, Srivastava AK, Xi L, Pham TH, Raffeld M, White DE, Toomey MA, Rosenberg SA, Kammula US. Treatment of metastatic uveal melanoma with adoptive transfer of tumour-infiltrating lymphocytes: a single-centre, two-stage, single-arm, phase 2 study. Lancet Oncol. 2017 06; 18(6):792-802. PMID: 28395880.
      Citations: 47     Fields:    Translation:HumansCellsCTClinical Trials
    116. Xu M, Yang J, Lieberman I, Haddas R. Finite element method-based study for effect of adult degenerative scoliosis on the spinal vibration characteristics. Comput Biol Med. 2017 05 01; 84:53-58. PMID: 28342408.
      Citations: 3     Fields:    Translation:Humans
    117. Kochenderfer JN, Somerville RPT, Lu T, Shi V, Bot A, Rossi J, Xue A, Goff SL, Yang JC, Sherry RM, Klebanoff CA, Kammula US, Sherman M, Perez A, Yuan CM, Feldman T, Friedberg JW, Roschewski MJ, Feldman SA, McIntyre L, Toomey MA, Rosenberg SA. Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels. J Clin Oncol. 2017 Jun 01; 35(16):1803-1813. PMID: 28291388.
      Citations: 99     Fields:    Translation:HumansCells
    118. Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol. 2017 May 01; 35(13):1403-1410. PMID: 28447912.
      Citations: 61     Fields:    Translation:Humans
    119. Yang JC. Debugging the Black Box. Cancer Discov. 2017 03; 7(3):250-251. PMID: 28264866.
      Citations:    Fields:    Translation:Humans
    120. Chang IS, Jiang SS, Yang JC, Su WC, Chien LH, Hsiao CF, Lee JH, Chen CY, Chen CH, Chang GC, Wang Z, Lo FY, Chen KY, Wang WC, Chen YM, Huang MS, Tsai YH, Su YC, Hsieh WS, Shih WC, Shieh SH, Yang TY, Lan Q, Rothman N, Chen CJ, Chanock SJ, Yang PC, Hsiung CA. Genetic Modifiers of Progression-Free Survival in Never-Smoking Lung Adenocarcinoma Patients Treated with First-Line Tyrosine Kinase Inhibitors. Am J Respir Crit Care Med. 2017 03 01; 195(5):663-673. PMID: 27669169.
      Citations: 6     Fields:    Translation:Humans
    121. Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component. J Clin Oncol. 2017 Apr 20; 35(12):1288-1296. PMID: 28221867.
      Citations: 115     Fields:    Translation:HumansCTClinical Trials
    122. Pati D, Valipoor S, Cloutier A, Yang J, Freier P, Harvey TE, Lee J. Physical Design Factors Contributing to Patient Falls. J Patient Saf. 2017 Feb 03. PMID: 28157790.
      Citations: 1     Fields:    
    123. Park TS, Phan GQ, Yang JC, Kammula U, Hughes MS, Trebska-McGowan K, Morton KE, White DE, Rosenberg SA, Sherry RM. Routine Computer Tomography Imaging for the Detection of Recurrences in High-Risk Melanoma Patients. Ann Surg Oncol. 2017 Apr; 24(4):947-951. PMID: 28144760.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    124. Liao BC, Lin CC, Yang JC. Novel EGFR Inhibitors in Non-small Cell Lung Cancer: Current Status of Afatinib. Curr Oncol Rep. 2017 Jan; 19(1):4. PMID: 28138934.
      Citations: 3     Fields:    Translation:Humans
    125. Lin YT, Liu YN, Wu SG, Yang JC, Shih JY. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-sensitive Exon 19 Insertion and Exon 20 Insertion in Patients With Advanced Non-Small-cell Lung Cancer. Clin Lung Cancer. 2017 05; 18(3):324-332.e1. PMID: 28089594.
      Citations: 7     Fields:    Translation:Humans
    126. Wu YL, Sequist LV, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Schuler M, Mok T, Yamamoto N, O'Byrne K, Hirsh V, Gibson N, Massey D, Kim M, Yang JC. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017 Jan 17; 116(2):175-185. PMID: 28006816.
      Citations: 18     Fields:    Translation:HumansCTClinical Trials
    127. Ding PN, Lord SJ, Gebski V, Links M, Bray V, Gralla RJ, Yang JC, Lee CK. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in Advanced EGFR-Mutated Non-Small Cell Lung Cancer. J Thorac Oncol. 2017 04; 12(4):633-643. PMID: 28007626.
      Citations: 23     Fields:    Translation:Humans
    128. Wu TH, Hsiue EH, Lee JH, Lin CC, Yang JC. New data on clinical decisions in NSCLC patients with uncommon EGFR mutations. Expert Rev Respir Med. 2017 01; 11(1):51-55. PMID: 27927060.
      Citations: 7     Fields:    Translation:Humans
    129. Yang Z, Guo Q, Wang Y, Chen K, Zhang L, Cheng Z, Xu Y, Yin X, Bai Y, Rabbie S, Kim DW, Ahn MJ, Yang JC, Zhang X. AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases. Sci Transl Med. 2016 12 07; 8(368):368ra172. PMID: 27928026.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    130. Yang JC, Puri T, Orlando M, Cheng Y. Reply to A. Ota et al, Y.H. Kim, and N. Van Der Steen et al. J Clin Oncol. 2017 02 20; 35(6):694-695. PMID: 27918723.
      Citations:    Fields:    Translation:Humans
    131. Ho CC, Liao WY, Lin CA, Shih JY, Yu CJ, Yang JC. Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib. J Thorac Oncol. 2017 03; 12(3):567-572. PMID: 27923714.
      Citations: 41     Fields:    Translation:HumansCells
    132. Liao BC, Lin CC, Lee JH, Yang JC. Update on recent preclinical and clinical studies of T790M mutant-specific irreversible epidermal growth factor receptor tyrosine kinase inhibitors. J Biomed Sci. 2016 Dec 03; 23(1):86. PMID: 27912760.
      Citations: 9     Fields:    Translation:Humans
    133. Lin KH, Hong ST, Wang HT, Lo YL, Lin AM, Yang JC. Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One a-Helical Cell-Penetrating Peptide or Glutathione and Tween 80. Int J Mol Sci. 2016 Nov 29; 17(12). PMID: 27916828.
      Citations: 4     Fields:    Translation:HumansCells
    134. Biswas R, Gao S, Cultraro CM, Maity TK, Venugopalan A, Abdullaev Z, Shaytan AK, Carter CA, Thomas A, Rajan A, Song Y, Pitts S, Chen K, Bass S, Boland J, Hanada KI, Chen J, Meltzer PS, Panchenko AR, Yang JC, Pack S, Giaccone G, Schrump DS, Khan J, Guha U. Genomic profiling of multiple sequentially acquired tumor metastatic sites from an "exceptional responder" lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response. Cold Spring Harb Mol Case Stud. 2016 11; 2(6):a001263. PMID: 27900369.
      Citations: 6     Fields:    Translation:HumansCells
    135. Wang QJ, Yu Z, Hanada KI, Patel K, Kleiner D, Restifo NP, Yang JC. Preclinical Evaluation of Chimeric Antigen Receptors Targeting CD70-Expressing Cancers. Clin Cancer Res. 2017 May 01; 23(9):2267-2276. PMID: 27803044.
      Citations: 13     Fields:    Translation:HumansAnimalsCells
    136. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, Han JY, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 12; 34(34):4079-4085. PMID: 27863201.
      Citations: 46     Fields:    Translation:HumansCTClinical Trials
    137. Hsiue EH, Lee JH, Lin CC, Yang JC. Profile of the therascreen® EGFR RGQ PCR kit as a companion diagnostic for gefitinib in non-small cell lung cancer. Expert Rev Mol Diagn. 2016 12; 16(12):1251-1257. PMID: 27737606.
      Citations: 3     Fields:    Translation:Humans
    138. Lee CK, Man J, Lord S, Links M, Gebski V, Mok T, Yang JC. Checkpoint Inhibitors in Metastatic EGFR-Mutated Non-Small Cell Lung Cancer-A Meta-Analysis. J Thorac Oncol. 2017 02; 12(2):403-407. PMID: 27765535.
      Citations: 159     Fields:    Translation:Humans
    139. Langer CJ, Gadgeel SM, Borghaei H, Papadimitrakopoulou VA, Patnaik A, Powell SF, Gentzler RD, Martins RG, Stevenson JP, Jalal SI, Panwalkar A, Yang JC, Gubens M, Sequist LV, Awad MM, Fiore J, Ge Y, Raftopoulos H, Gandhi L. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016 Nov; 17(11):1497-1508. PMID: 27745820.
      Citations: 372     Fields:    Translation:HumansCTClinical Trials
    140. Manegold C, Dingemans AC, Gray JE, Nakagawa K, Nicolson M, Peters S, Reck M, Wu YL, Brustugun OT, Crinò L, Felip E, Fennell D, Garrido P, Huber RM, Marabelle A, Moniuszko M, Mornex F, Novello S, Papotti M, Pérol M, Smit EF, Syrigos K, van Meerbeeck JP, van Zandwijk N, Yang JC, Zhou C, Vokes E. The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. J Thorac Oncol. 2017 02; 12(2):194-207. PMID: 27729297.
      Citations: 43     Fields:    Translation:Humans
    141. Gragg J, Klose E, Yang J. Modelling the stochastic nature of the available coefficient of friction at footwear-floor interfaces. Ergonomics. 2017 Jul; 60(7):977-984. PMID: 27592564.
      Citations:    Fields:    Translation:Humans
    142. Klemen ND, Feingold PL, Goff SL, Hughes MS, Kammula US, Yang JC, Schrump DS, Rosenberg SA, Sherry RM. Metastasectomy Following Immunotherapy with Adoptive Cell Transfer for Patients with Advanced Melanoma. Ann Surg Oncol. 2017 Jan; 24(1):135-141. PMID: 27638681.
      Citations: 5     Fields:    Translation:Humans
    143. Lu SL, Hsu FM, Chen KY, Ho CC, Yang JC, Cheng JC. Maximizing Benefits from Maintenance Pemetrexed with Stereotactic Ablative Radiotherapy in Oligoprogressive Non-Squamous Non-Small Cell Lung Cancer. Case Rep Oncol. 2016 May-Aug; 9(2):474-480. PMID: 27721771.
    144. Cheng Y, Murakami H, Yang PC, He J, Nakagawa K, Kang JH, Kim JH, Wang X, Enatsu S, Puri T, Orlando M, Yang JC. Randomized Phase II Trial of Gefitinib With and Without Pemetrexed as First-Line Therapy in Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations. J Clin Oncol. 2016 09 20; 34(27):3258-66. PMID: 27507876.
      Citations: 28     Fields:    Translation:HumansCellsCTClinical Trials
    145. Mok TS, Geater SL, Su WC, Tan EH, Yang JC, Chang GC, Han M, Komarnitsky P, Payumo F, Garrus JE, Close S, Park K. A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary Adenocarcinoma. J Thorac Oncol. 2016 10; 11(10):1736-44. PMID: 27448761.
      Citations: 12     Fields:    Translation:HumansCTClinical Trials
    146. Ballard P, Yates JW, Yang Z, Kim DW, Yang JC, Cantarini M, Pickup K, Jordan A, Hickey M, Grist M, Box M, Johnström P, Varnäs K, Malmquist J, Thress KS, Jänne PA, Cross D. Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity. Clin Cancer Res. 2016 Oct 15; 22(20):5130-5140. PMID: 27435396.
      Citations: 117     Fields:    Translation:HumansAnimalsCells
    147. Liang YH, Shao YY, Liao BC, Lee HS, Yang JC, Chen HM, Chiang CJ, Cheng AL, Lai MS. Cytotoxic Chemotherapy as First-Line Therapy for Advanced Non-Small-Cell Lung Cancer in Taiwan: Daily Practice. J Cancer. 2016; 7(11):1515-23. PMID: 27471567.
    148. Oxnard GR, Thress KS, Alden RS, Lawrance R, Paweletz CP, Cantarini M, Yang JC, Barrett JC, Jänne PA. Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2016 10 01; 34(28):3375-82. PMID: 27354477.
      Citations: 205     Fields:    Translation:HumansCTClinical Trials
    149. Xu M, Yang J, Lieberman IH, Haddas R. Lumbar spine finite element model for healthy subjects: development and validation. Comput Methods Biomech Biomed Engin. 2017 Jan; 20(1):1-15. PMID: 27315668.
      Citations: 3     Fields:    Translation:Humans
    150. Hsiue EH, Lee JH, Lin CC, Yang JC. Safety of gefitinib in non-small cell lung cancer treatment. Expert Opin Drug Saf. 2016 Jul; 15(7):993-1000. PMID: 27212579.
      Citations: 1     Fields:    Translation:Humans
    151. Goff SL, Dudley ME, Citrin DE, Somerville RP, Wunderlich JR, Danforth DN, Zlott DA, Yang JC, Sherry RM, Kammula US, Klebanoff CA, Hughes MS, Restifo NP, Langhan MM, Shelton TE, Lu L, Kwong ML, Ilyas S, Klemen ND, Payabyab EC, Morton KE, Toomey MA, Steinberg SM, White DE, Rosenberg SA. Randomized, Prospective Evaluation Comparing Intensity of Lymphodepletion Before Adoptive Transfer of Tumor-Infiltrating Lymphocytes for Patients With Metastatic Melanoma. J Clin Oncol. 2016 07 10; 34(20):2389-97. PMID: 27217459.
      Citations: 81     Fields:    Translation:HumansCells
    152. Chen YF, Hsieh MS, Wu SG, Chang YL, Yu CJ, Yang JC, Yang PC, Shih JY. Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion-Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations in East Asian Populations. J Thorac Oncol. 2016 07; 11(7):1140-52. PMID: 27094798.
      Citations: 20     Fields:    Translation:Humans
    153. Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. Lancet Oncol. 2016 05; 17(5):577-89. PMID: 27083334.
      Citations: 208     Fields:    Translation:HumansCTClinical Trials
    154. Lin YT, Yu CJ, Yang JC, Shih JY. Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non-Small-Cell Lung Cancer: Analysis and Literature Review. Clin Lung Cancer. 2016 09; 17(5):e77-e94. PMID: 27130468.
      Citations: 6     Fields:    Translation:Humans
    155. Wu SG, Liu YN, Tsai MF, Chang YL, Yu CJ, Yang PC, Yang JC, Wen YF, Shih JY. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget. 2016 Mar 15; 7(11):12404-13. PMID: 26862733.
      Citations: 59     Fields:    Translation:HumansCells
    156. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, Prickett TD, Gartner JJ, Crystal JS, Roberts IM, Trebska-McGowan K, Wunderlich JR, Yang JC, Rosenberg SA. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med. 2016 Apr; 22(4):433-8. PMID: 26901407.
      Citations: 209     Fields:    Translation:HumansCells
    157. Yang JC, Rosenberg SA. Adoptive T-Cell Therapy for Cancer. Adv Immunol. 2016; 130:279-94. PMID: 26923004.
      Citations: 55     Fields:    Translation:HumansAnimalsCells
    158. Chen LY, Molina-Vila MA, Ruan SY, Su KY, Liao WY, Yu KL, Ho CC, Shih JY, Yu CJ, Yang JC, Rosell R, Yang PC. Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer: A systematic review and meta-analysis. Lung Cancer. 2016 Apr; 94:46-53. PMID: 26973206.
      Citations: 21     Fields:    Translation:Humans
    159. Schuler M, Wu YL, Hirsh V, O'Byrne K, Yamamoto N, Mok T, Popat S, Sequist LV, Massey D, Zazulina V, Yang JC. First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. J Thorac Oncol. 2016 Mar; 11(3):380-90. PMID: 26823294.
      Citations: 70     Fields:    Translation:HumansCTClinical Trials
    160. Chiang Y, Yang JC, Hsu FM, Chen YH, Shih JY, Lin ZZ, Lan KH, Cheng AL, Kuo SH. The Response, Outcome and Toxicity of Aggressive Palliative Thoracic Radiotherapy for Metastatic Non-Small Cell Lung Cancer Patients with Controlled Extrathoracic Diseases. PLoS One. 2015; 10(12):e0145936. PMID: 26720170.
      Citations: 6     Fields:    Translation:Humans
    161. Yang JC, Srimuninnimit V, Ahn MJ, Lin CC, Kim SW, Tsai CM, Mok T, Orlando M, Puri T, Wang X, Park K. First-Line Pemetrexed plus Cisplatin followed by Gefitinib Maintenance Therapy versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer: Final Overall Survival Results from a Randomized Phase 3 Study. J Thorac Oncol. 2016 Mar; 11(3):370-9. PMID: 26725183.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    162. Wang QJ, Yu Z, Griffith K, Hanada K, Restifo NP, Yang JC. Identification of T-cell Receptors Targeting KRAS-Mutated Human Tumors. Cancer Immunol Res. 2016 Mar; 4(3):204-14. PMID: 26701267.
      Citations: 41     Fields:    Translation:HumansAnimalsCells
    163. Boye M, Wang X, Srimuninnimit V, Kang JH, Tsai CM, Orlando M, Puri T, Kim JS, Rajan N, Yang JC. First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial. Clin Lung Cancer. 2016 Mar; 17(2):150-60. PMID: 26809984.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    164. Ilyas S, Yang JC. Landscape of Tumor Antigens in T Cell Immunotherapy. J Immunol. 2015 Dec 01; 195(11):5117-22. PMID: 26589749.
      Citations: 29     Fields:    Translation:HumansCells
    165. Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhász E, Arén O, Sun Y, Schmelter T, Ong TJ, Peña C, Smit EF, Mok TS. Monotherapy Administration of Sorafenib in Patients With Non-Small Cell Lung Cancer (MISSION) Trial: A Phase III, Multicenter, Placebo-Controlled Trial of Sorafenib in Patients with Relapsed or Refractory Predominantly Nonsquamous Non-Small-Cell Lung Cancer after 2 or 3 Previous Treatment Regimens. J Thorac Oncol. 2015 Dec; 10(12):1745-53. PMID: 26743856.
      Citations: 29     Fields:    Translation:HumansCTClinical Trials
    166. Liao BC, Lee JH, Lin CC, Chen YF, Chang CH, Ho CC, Shih JY, Yu CJ, Yang JC. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-Small-Cell Lung Cancer Patients with Leptomeningeal Carcinomatosis. J Thorac Oncol. 2015 Dec; 10(12):1754-61. PMID: 26334749.
      Citations: 26     Fields:    Translation:Humans
    167. Ou SH, Ahn JS, De Petris L, Govindan R, Yang JC, Hughes B, Lena H, Moro-Sibilot D, Bearz A, Ramirez SV, Mekhail T, Spira A, Bordogna W, Balas B, Morcos PN, Monnet A, Zeaiter A, Kim DW. Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study. J Clin Oncol. 2016 Mar 01; 34(7):661-8. PMID: 26598747.
      Citations: 181     Fields:    Translation:HumansCTClinical Trials
    168. Yang JC. Toxicities Associated With Adoptive T-Cell Transfer for Cancer. Cancer J. 2015 Nov-Dec; 21(6):506-9. PMID: 26588684.
      Citations: 7     Fields:    Translation:HumansCells
    169. Yang JC. The Immunotherapy Roadmap. Clin Cancer Res. 2016 Jan 15; 22(2):275-6. PMID: 26459176.
      Citations:    Fields:    Translation:Humans
    170. Wu H, Shih JY, Yang JC. Rapid Response to Sunitinib in a Patient with Lung Adenocarcinoma Harboring KIF5B-RET Fusion Gene. J Thorac Oncol. 2015 Sep; 10(9):e95-e96. PMID: 26291023.
      Citations: 4     Fields:    Translation:Humans
    171. Liao BC, Lin CC, Shih JY, Yang JC. Treating patients with ALK-positive non-small cell lung cancer: latest evidence and management strategy. Ther Adv Med Oncol. 2015 Sep; 7(5):274-90. PMID: 26327925.
    172. Kuo HY, Lin ZZ, Kuo R, Shau WY, Lai CL, Yang YY, Shao YY, Hsu C, Cheng WF, Cheng AL, Yang JC, Lai MS. The Prognostic Impact of Type 2 Diabetes Mellitus on Early Cervical Cancer in Asia. Oncologist. 2015 Sep; 20(9):1051-7. PMID: 26240133.
      Citations: 3     Fields:    Translation:Humans
    173. Soria JC, Wu YL, Nakagawa K, Kim SW, Yang JJ, Ahn MJ, Wang J, Yang JC, Lu Y, Atagi S, Ponce S, Lee DH, Liu Y, Yoh K, Zhou JY, Shi X, Webster A, Jiang H, Mok TS. Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial. Lancet Oncol. 2015 Aug; 16(8):990-8. PMID: 26159065.
      Citations: 111     Fields:    Translation:HumansCTClinical Trials
    174. Yang JC, Sequist LV, Geater SL, Tsai CM, Mok TS, Schuler M, Yamamoto N, Yu CJ, Ou SH, Zhou C, Massey D, Zazulina V, Wu YL. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncol. 2015 Jul; 16(7):830-8. PMID: 26051236.
      Citations: 163     Fields:    Translation:HumansCTClinical Trials
    175. Tang C, Hess K, Bishop AJ, Pan HY, Christensen EN, Yang JN, Tannir N, Amini B, Tatsui C, Rhines L, Brown P, Ghia A. Creation of a Prognostic Index for Spine Metastasis to Stratify Survival in Patients Treated With Spinal Stereotactic Radiosurgery: Secondary Analysis of Mature Prospective Trials. Int J Radiat Oncol Biol Phys. 2015 Sep 01; 93(1):118-25. PMID: 26130231.
      Citations: 8     Fields:    Translation:HumansCTClinical Trials
    176. Jänne PA, Yang JC, Kim DW, Planchard D, Ohe Y, Ramalingam SS, Ahn MJ, Kim SW, Su WC, Horn L, Haggstrom D, Felip E, Kim JH, Frewer P, Cantarini M, Brown KH, Dickinson PA, Ghiorghiu S, Ranson M. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med. 2015 Apr 30; 372(18):1689-99. PMID: 25923549.
      Citations: 533     Fields:    Translation:HumansCTClinical Trials
    177. Liu YN, Chang TH, Tsai MF, Wu SG, Tsai TH, Chen HY, Yu SL, Yang JC, Shih JY. IL-8 confers resistance to EGFR inhibitors by inducing stem cell properties in lung cancer. Oncotarget. 2015 Apr 30; 6(12):10415-31. PMID: 25871388.
      Citations: 24     Fields:    Translation:HumansAnimalsCells
    178. Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015 Jun 20; 33(18):2092-9. PMID: 25918278.
      Citations: 131     Fields:    Translation:HumansCells
    179. Lee CK, Wu YL, Ding PN, Lord SJ, Inoue A, Zhou C, Mitsudomi T, Rosell R, Pavlakis N, Links M, Gebski V, Gralla RJ, Yang JC. Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis. J Clin Oncol. 2015 Jun 10; 33(17):1958-65. PMID: 25897154.
      Citations: 86     Fields:    Translation:Humans
    180. Stevanovic S, Draper LM, Langhan MM, Campbell TE, Kwong ML, Wunderlich JR, Dudley ME, Yang JC, Sherry RM, Kammula US, Restifo NP, Rosenberg SA, Hinrichs CS. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol. 2015 May 10; 33(14):1543-50. PMID: 25823737.
      Citations: 133     Fields:    Translation:HumansCells
    181. Tang MC, Wu MY, Hwang MH, Chang YT, Huang HJ, Lin AM, Yang JC. Chloroquine enhances gefitinib cytotoxicity in gefitinib-resistant nonsmall cell lung cancer cells. PLoS One. 2015; 10(3):e0119135. PMID: 25807554.
      Citations: 23     Fields:    Translation:HumansCells
    182. Tsai TH, Wu SG, Hsieh MS, Yu CJ, Yang JC, Shih JY. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion. Lung Cancer. 2015 May; 88(2):208-14. PMID: 25773866.
      Citations: 10     Fields:    Translation:Humans
    183. Liao BC, Lin CC, Yang JC. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer. Curr Opin Oncol. 2015 Mar; 27(2):94-101. PMID: 25611025.
      Citations: 31     Fields:    Translation:Humans
    184. Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC, Rosenberg SA. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res. 2015 May 15; 21(10):2278-88. PMID: 25695689.
      Citations: 77     Fields:    Translation:HumansCellsCTClinical Trials
    185. Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb; 16(2):141-51. PMID: 25589191.
      Citations: 407     Fields:    Translation:HumansCTClinical Trials
    186. Gragg J, Yang J. Predicting the probability of slip in gait: methodology and distribution study. Comput Methods Biomech Biomed Engin. 2016; 19(1):93-100. PMID: 25563532.
      Citations:    Fields:    Translation:Humans
    187. Xu M, Lei Z, Yang J. Estimating the Dead Space Volume Between a Headform and N95 Filtering Facepiece Respirator Using Microsoft Kinect. J Occup Environ Hyg. 2015; 12(8):538-46. PMID: 25800663.
      Citations:    Fields:    Translation:PHPublic Health
    188. Robbins PF, Kassim SH, Tran TL, Crystal JS, Morgan RA, Feldman SA, Yang JC, Dudley ME, Wunderlich JR, Sherry RM, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Li YF, El-Gamil M, Rosenberg SA. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015 Mar 01; 21(5):1019-27. PMID: 25538264.
      Citations: 189     Fields:    Translation:HumansCellsCTClinical Trials
    189. Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Dudley ME, Somerville R, Wunderlich JR, Sherry RM, Yang JC, Rosenberg SA, Kammula US. Persistence of CTL clones targeting melanocyte differentiation antigens was insufficient to mediate significant melanoma regression in humans. Clin Cancer Res. 2015 Feb 01; 21(3):534-43. PMID: 25424856.
      Citations: 17     Fields:    Translation:HumansCellsCTClinical Trials
    190. Klawikowski SJ, Yang JN, Adamovics J, Ibbott GS. PRESAGE 3D dosimetry accurately measures Gamma Knife output factors. Phys Med Biol. 2014 Dec 07; 59(23):N211-20. PMID: 25368961.
      Citations: 1     Fields:    
    191. Lin YT, Wang YF, Yang JC, Yu CJ, Wu SG, Shih JY, Yang PC. Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer. J Thorac Oncol. 2014 Nov; 9(11):1720-5. PMID: 25436806.
      Citations: 16     Fields:    Translation:Humans
    192. Yang JC, Sherry RM. MSLT-I-response of clinical trial investigators. Nat Rev Clin Oncol. 2014 Nov; 11(11). PMID: 25311346.
      Citations:    Fields:    Translation:Humans
    193. Liao BC, Shao YY, Chen HM, Shau WY, Lin ZZ, Kuo RN, Lai CL, Chen KH, Cheng AL, Yang JC, Lai MS. Comparative effectiveness of first-line platinum-based chemotherapy regimens for advanced lung squamous cell carcinoma. Clin Lung Cancer. 2015 Mar; 16(2):137-43. PMID: 25450871.
      Citations: 5     Fields:    Translation:Humans
    194. Hsu CL, Chen JH, Chen KY, Shih JY, Yang JC, Yu CJ, Yang PC. Advanced non-small cell lung cancer in the elderly: the impact of age and comorbidities on treatment modalities and patient prognosis. J Geriatr Oncol. 2015 Jan; 6(1):38-45. PMID: 25245172.
      Citations: 10     Fields:    Translation:Humans
    195. Lei Z, Ji X, Li N, Yang J, Zhuang Z, Rottach D. Simulated effects of head movement on contact pressures between headforms and N95 filtering facepiece respirators-part 1: headform model and validation. Ann Occup Hyg. 2014 Nov; 58(9):1175-85. PMID: 25187034.
      Citations:    Fields:    Translation:HumansPHPublic Health
    196. Lei Z, Ji X, Li N, Yang J, Zhuang Z, Rottach D. Simulated effects of head movement on contact pressures between headforms and N95 filtering facepiece respirators part 2: simulation. Ann Occup Hyg. 2014 Nov; 58(9):1186-99. PMID: 25187035.
      Citations: 3     Fields:    Translation:HumansPHPublic Health
    197. Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Marsland T, Patel T, Rubin M, White L, Yang JC, Klughammer B, Colburn D, Miller V, Johnson BE. Biomarker analyses from a randomized, placebo-controlled, phase IIIb trial comparing bevacizumab with or without erlotinib as maintenance therapy for the treatment of advanced non-small-cell lung cancer (ATLAS). J Thorac Oncol. 2014 Sep; 9(9):1411-7. PMID: 25122437.
      Citations: 4     Fields:    Translation:HumansCTClinical Trials
    198. Blagoev KB, Wilkerson J, Stein WD, Yang J, Bates SE, Fojo T. Therapies with diverse mechanisms of action kill cells by a similar exponential process in advanced cancers. Cancer Res. 2014 Sep 01; 74(17):4653-62. PMID: 25183789.
      Citations: 2     Fields:    Translation:HumansAnimals
    199. Lee JH, Lin YL, Hsu WH, Chen HY, Chang YC, Yu CJ, Shih JY, Lin CC, Chen KY, Ho CC, Laio WY, Yang PC, Yang JC. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer. J Thorac Oncol. 2014 Sep; 9(9):1385-92. PMID: 25057939.
      Citations: 20     Fields:    Translation:Humans
    200. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20; 33(6):540-9. PMID: 25154820.
      Citations: 492     Fields:    Translation:HumansCellsCTClinical Trials
    201. Chen YF, Hsieh MS, Wu SG, Chang YL, Shih JY, Liu YN, Tsai MF, Tsai TH, Yu CJ, Yang JC, Yang PC. Clinical and the prognostic characteristics of lung adenocarcinoma patients with ROS1 fusion in comparison with other driver mutations in East Asian populations. J Thorac Oncol. 2014 Aug; 9(8):1171-9. PMID: 25157770.
      Citations: 17     Fields:    Translation:Humans
    202. Lu YC, Yao X, Crystal JS, Li YF, El-Gamil M, Gross C, Davis L, Dudley ME, Yang JC, Samuels Y, Rosenberg SA, Robbins PF. Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014 Jul 01; 20(13):3401-10. PMID: 24987109.
      Citations: 121     Fields:    Translation:HumansAnimalsCells
    203. Yang JC, Kang JH, Mok T, Ahn MJ, Srimuninnimit V, Lin CC, Kim DW, Tsai CM, Barraclough H, Altug S, Orlando M, Park K. First-line pemetrexed plus cisplatin followed by gefitinib maintenance therapy versus gefitinib monotherapy in East Asian patients with locally advanced or metastatic non-squamous non-small cell lung cancer: a randomised, phase 3 trial. Eur J Cancer. 2014 Sep; 50(13):2219-30. PMID: 24953333.
      Citations: 9     Fields:    Translation:HumansCTClinical Trials
    204. Popat S, Mok T, Yang JC, Wu YL, Lungershausen J, Stammberger U, Griebsch I, Fonseca T, Paz-Ares L. Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis. Lung Cancer. 2014 Aug; 85(2):230-8. PMID: 24929780.
      Citations: 16     Fields:    Translation:Humans
    205. Li J, Yang J, Levin AM, Montgomery CG, Datta I, Trudeau S, Adrianto I, McKeigue P, Iannuzzi MC, Rybicki BA. Efficient generalized least squares method for mixed population and family-based samples in genome-wide association studies. Genet Epidemiol. 2014 Jul; 38(5):430-8. PMID: 24845555.
      Citations: 6     Fields:    Translation:Humans
    206. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, Parkhurst MR, Yang JC, Rosenberg SA. Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014 May 09; 344(6184):641-5. PMID: 24812403.
      Citations: 480     Fields:    Translation:HumansCells
    207. Beane JD, Yang JC, White D, Steinberg SM, Rosenberg SA, Rudloff U. Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial. Ann Surg Oncol. 2014 Aug; 21(8):2484-9. PMID: 24756814.
      Citations: 39     Fields:    Translation:Humans
    208. Shtivelman E, Davies MQ, Hwu P, Yang J, Lotem M, Oren M, Flaherty KT, Fisher DE. Pathways and therapeutic targets in melanoma. Oncotarget. 2014 Apr 15; 5(7):1701-52. PMID: 24743024.
      Citations: 68     Fields:    Translation:HumansAnimalsCells
    209. Yang JC, Sherry RM, Rosenberg SA. Melanoma: Why is sentinel lymph node biopsy 'standard of care' for melanoma? Nat Rev Clin Oncol. 2014 May; 11(5):245-6. PMID: 24732941.
      Citations: 5     Fields:    Translation:Humans
    210. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, Hanada K, Almeida JR, Darko S, Douek DC, Yang JC, Rosenberg SA. PD-1 identifies the patient-specific CD8? tumor-reactive repertoire infiltrating human tumors. J Clin Invest. 2014 May; 124(5):2246-59. PMID: 24667641.
      Citations: 290     Fields:    Translation:HumansCellsCTClinical Trials
    211. Yang JC, Sequist LV. Reply to F. De Marinis et al. J Clin Oncol. 2014 Mar 10; 32(8):865. PMID: 24493733.
      Citations:    Fields:    Translation:Humans
    212. Yang JC, Sequist LV. Reply to E.R. Haspinger et al. J Clin Oncol. 2014 Mar 10; 32(8):863-4. PMID: 24493734.
      Citations:    Fields:    Translation:Humans
    213. Tseng J, Citrin DE, Waldman M, White DE, Rosenberg SA, Yang JC. Thrombotic microangiopathy in metastatic melanoma patients treated with adoptive cell therapy and total body irradiation. Cancer. 2014 May 01; 120(9):1426-32. PMID: 24474396.
      Citations: 5     Fields:    Translation:HumansCellsPHPublic Health
    214. Kao HF, Chen IC, Hsu C, Chang SY, Chien SF, Chen YC, Hu FC, Yang JC, Cheng AL, Yeh KH. Chlorhexidine for the prevention of bloodstream infection associated with totally implantable venous ports in patients with solid cancers. Support Care Cancer. 2014 May; 22(5):1189-97. PMID: 24384684.
      Citations: 2     Fields:    Translation:HumansCTClinical Trials
    215. Lei Z, Yang J, Zhuang Z. A novel algorithm for determining contact area between a respirator and a headform. J Occup Environ Hyg. 2014; 11(4):227-37. PMID: 24579752.
      Citations:    Fields:    Translation:HumansPHPublic Health
    216. Gridelli C, de Marinis F, Cappuzzo F, Di Maio M, Hirsch FR, Mok T, Morgillo F, Rosell R, Spigel DR, Yang JC, Ciardiello F. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology. Clin Lung Cancer. 2014 May; 15(3):173-81. PMID: 24486058.
      Citations: 24     Fields:    Translation:Humans
    217. Yang JC, Wu YL, Chan V, Kurnianda J, Nakagawa K, Saijo N, Fukuoka M, McWalter G, McCormack R, Mok TS. Epidermal growth factor receptor mutation analysis in previously unanalyzed histology samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer. 2014 Feb; 83(2):174-81. PMID: 24361280.
      Citations: 19     Fields:    Translation:HumansCTClinical Trials
    218. Ghamande S, Lin CC, Cho DC, Shapiro GI, Kwak EL, Silverman MH, Tseng Y, Kuo MW, Mach WB, Hsu SC, Coleman T, Yang JC, Cheng AL, Ghalib MH, Chuadhary I, Goel S. A phase 1 open-label, sequential dose-escalation study investigating the safety, tolerability, and pharmacokinetics of intravenous TLC388 administered to patients with advanced solid tumors. Invest New Drugs. 2014 Jun; 32(3):445-51. PMID: 24271274.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    219. Lin ZZ, Shau WY, Hsu C, Shao YY, Yeh YC, Kuo RN, Hsu CH, Yang JC, Cheng AL, Lai MS. Radiofrequency ablation is superior to ethanol injection in early-stage hepatocellular carcinoma irrespective of tumor size. PLoS One. 2013; 8(11):e80276. PMID: 24244668.
      Citations: 10     Fields:    Translation:Humans
    220. Tsai TH, Yang CY, Ho CC, Liao WY, Jan IS, Chen KY, Wang JY, Ruan SY, Yu CJ, Yang JC, Yang PC, Shih JY. Multi-gene analyses from waste brushing specimens for patients with peripheral lung cancer receiving EBUS-assisted bronchoscopy. Lung Cancer. 2013 Dec; 82(3):420-5. PMID: 24183104.
      Citations: 11     Fields:    Translation:HumansCellsPHPublic Health
    221. Johnson BE, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B, Lin CY, Marsland T, Patel T, Polikoff J, Rubin M, White L, Yang JC, Bowden C, Miller V. ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013 Nov 01; 31(31):3926-34. PMID: 24101054.
      Citations: 55     Fields:    Translation:HumansCTClinical Trials
    222. Kwong ML, Neyns B, Yang JC. Adoptive T-cell transfer therapy and oncogene-targeted therapy for melanoma: the search for synergy. Clin Cancer Res. 2013 Oct 01; 19(19):5292-9. PMID: 24089442.
      Citations: 4     Fields:    Translation:HumansAnimalsCells
    223. Wang X, Yang JN, Li X, Tailor R, Vassilliev O, Brown P, Rhines L, Chang E. Effect of spine hardware on small spinal stereotactic radiosurgery dosimetry. Phys Med Biol. 2013 Oct 07; 58(19):6733-47. PMID: 24018829.
      Citations: 6     Fields:    Translation:Humans
    224. Abate-Daga D, Hanada K, Davis JL, Yang JC, Rosenberg SA, Morgan RA. Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes. Blood. 2013 Aug 22; 122(8):1399-410. PMID: 23861247.
      Citations: 36     Fields:    Translation:HumansAnimalsCells
    225. Wu PF, Huang WC, Yang JC, Lu YS, Shih JY, Wu SG, Lin CH, Cheng AL. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas. J Neurooncol. 2013 Oct; 115(1):61-70. PMID: 23817810.
      Citations: 4     Fields:    Translation:HumansCells
    226. Kao HF, Lin CC, Yang JC. EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer. Future Oncol. 2013 Jul; 9(7):991-1003. PMID: 23837762.
      Citations: 4     Fields:    Translation:Humans
    227. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3327-34. PMID: 23816960.
      Citations: 842     Fields:    Translation:HumansCTClinical Trials
    228. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, Zazulina V, Shahidi M, Lungershausen J, Massey D, Palmer M, Sequist LV. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20; 31(27):3342-50. PMID: 23816967.
      Citations: 96     Fields:    Translation:HumansCTClinical Trials
    229. Lu YC, Yao X, Li YF, El-Gamil M, Dudley ME, Yang JC, Almeida JR, Douek DC, Samuels Y, Rosenberg SA, Robbins PF. Mutated PPP1R3B is recognized by T cells used to treat a melanoma patient who experienced a durable complete tumor regression. J Immunol. 2013 Jun 15; 190(12):6034-42. PMID: 23690473.
      Citations: 59     Fields:    Translation:HumansCells
    230. Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA. Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol. 2013 Jun 10; 31(17):2152-9. PMID: 23650429.
      Citations: 67     Fields:    Translation:HumansCellsCTClinical Trials
    231. Yang JC. A selective ALK inhibitor in ALK-rearranged patients. Lancet Oncol. 2013 Jun; 14(7):564-5. PMID: 23639469.
      Citations: 5     Fields:    Translation:Humans
    232. Lee CK, Brown C, Gralla RJ, Hirsh V, Thongprasert S, Tsai CM, Tan EH, Ho JC, Chu da T, Zaatar A, Osorio Sanchez JA, Vu VV, Au JS, Inoue A, Lee SM, Gebski V, Yang JC. Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis. J Natl Cancer Inst. 2013 May 01; 105(9):595-605. PMID: 23594426.
      Citations: 160     Fields:    Translation:Humans
    233. Wu YL, Fukuoka M, Mok TS, Saijo N, Thongprasert S, Yang JC, Chu DT, Yang JJ, Rukazenkov Y. Tumor response and health-related quality of life in clinically selected patients from Asia with advanced non-small-cell lung cancer treated with first-line gefitinib: post hoc analyses from the IPASS study. Lung Cancer. 2013 Aug; 81(2):280-7. PMID: 23540718.
      Citations: 16     Fields:    Translation:Humans
    234. Long J, Yang J, Lei Z, Liang D. Simulation-based assessment for construction helmets. Comput Methods Biomech Biomed Engin. 2015; 18(1):24-37. PMID: 23495784.
      Citations: 1     Fields:    Translation:Humans
    235. Yang JC, Reguart N, Barinoff J, Köhler J, Uttenreuther-Fischer M, Stammberger U, O'Brien D, Wolf J, Cohen EE. Diarrhea associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther. 2013 Jun; 13(6):729-36. PMID: 23506556.
      Citations: 20     Fields:    Translation:Humans
    236. Yang JC. The adoptive transfer of cultured T cells for patients with metastatic melanoma. Clin Dermatol. 2013 Mar-Apr; 31(2):209-19. PMID: 23438384.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    237. Liao BC, Lin CC, Yang JC. First-line management of EGFR-mutated advanced lung adenocarcinoma: recent developments. Drugs. 2013 Mar; 73(4):357-69. PMID: 23479407.
      Citations: 7     Fields:    Translation:Humans
    238. Hirsh V, Cadranel J, Cong XJ, Fairclough D, Finnern HW, Lorence RM, Miller VA, Palmer M, Yang JC. Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). J Thorac Oncol. 2013 Feb; 8(2):229-37. PMID: 23328549.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    239. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013 Feb; 36(2):133-51. PMID: 23377668.
      Citations: 337     Fields:    Translation:HumansCellsCTClinical Trials
    240. Liao WY, Chen JH, Wu M, Shih JY, Chen KY, Ho CC, Yang JC, Yu CJ. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer. Clin Lung Cancer. 2013 Jul; 14(4):418-24. PMID: 23291258.
      Citations: 5     Fields:    Translation:Humans
    241. Cloutier A, Yang J. Design, control, and sensory feedback of externally powered hand prostheses: a literature review. Crit Rev Biomed Eng. 2013; 41(2):161-81. PMID: 24580569.
      Citations: 6     Fields:    Translation:Humans
    242. Lei Z, Yang J, Zhuang Z, Roberge R. Simulation and evaluation of respirator faceseal leaks using computational fluid dynamics and infrared imaging. Ann Occup Hyg. 2013 May; 57(4):493-506. PMID: 23243192.
      Citations: 10     Fields:    Translation:HumansCellsPHPublic Health
    243. Wang QJ, Hanada K, Robbins PF, Li YF, Yang JC. Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma. Cancer Res. 2012 Dec 01; 72(23):6119-29. PMID: 23071066.
      Citations: 25     Fields:    Translation:HumansCells
    244. Huang MH, Lee JH, Chang YJ, Tsai HH, Lin YL, Lin AM, Yang JC. MEK inhibitors reverse resistance in epidermal growth factor receptor mutation lung cancer cells with acquired resistance to gefitinib. Mol Oncol. 2013 Feb; 7(1):112-20. PMID: 23102728.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    245. Silich B, Chrobak P, Siu J, Schlichting A, Patel S, Yang J. Improving safety and efficiency during emergent central venous catheter placement with a needleless securing clamp. Emerg Med J. 2013 Aug; 30(8):683-6. PMID: 22962092.
      Citations: 1     Fields:    Translation:Humans
    246. Liao BC, Yang JC. Front-line erlotinib in unselected patient with advanced NSCLC followed by standard chemotherapy with gemcitabine and cisplatin - TORCH study. Transl Lung Cancer Res. 2012 Sep; 1(3):227-9. PMID: 25806186.
    247. Yang JC. Small-cell lung cancer treatment: where is the target? J Thorac Oncol. 2012 Sep; 7(9):1327-8. PMID: 22895135.
      Citations:    Fields:    Translation:Humans
    248. Huang CP, Tsai MF, Chang TH, Tang WC, Chen SY, Lai HH, Lin TY, Yang JC, Yang PC, Shih JY, Lin SB. ALDH-positive lung cancer stem cells confer resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Cancer Lett. 2013 Jan 01; 328(1):144-51. PMID: 22935675.
      Citations: 43     Fields:    Translation:HumansAnimalsCells
    249. Shao YY, Shau WY, Lin ZZ, Chen HM, Kuo R, Yang JC, Lai MS. Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer. Eur J Cancer. 2013 Jan; 49(1):106-14. PMID: 22897841.
      Citations: 8     Fields:    Translation:Humans
    250. Lin ZZ, Shau WY, Shao YY, Yang YY, Kuo RN, Yang JC, Lai MS. Survival following surgery with or without adjuvant chemotherapy for stage I-IIIA non-small cell lung cancer: an east asian population-based study. Oncologist. 2012; 17(10):1294-302. PMID: 22826374.
      Citations: 3     Fields:    Translation:Humans
    251. Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K, Aoe K, Toyooka S, Kiura K, Fernandez-Cuesta L, Fidias P, Yang JC, Miller VA, Riely GJ, Kris MG, Engelman JA, Vnencak-Jones CL, Dias-Santagata D, Ladanyi M, Pao W. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. Proc Natl Acad Sci U S A. 2012 Jul 31; 109(31):E2127-33. PMID: 22773810.
      Citations: 184     Fields:    Translation:HumansCells
    252. Liao WY, Shih JY, Chang GC, Cheng YK, Yang JC, Chen YM, Yu CJ. Genetic polymorphism of XRCC1 Arg399Gln is associated with survival in non-small-cell lung cancer patients treated with gemcitabine/platinum. J Thorac Oncol. 2012 Jun; 7(6):973-81. PMID: 22551904.
      Citations: 23     Fields:    Translation:Humans
    253. Friedman KM, Prieto PA, Devillier LE, Gross CA, Yang JC, Wunderlich JR, Rosenberg SA, Dudley ME. Tumor-specific CD4+ melanoma tumor-infiltrating lymphocytes. J Immunother. 2012 Jun; 35(5):400-8. PMID: 22576345.
      Citations: 33     Fields:    Translation:HumansCells
    254. Seaman BJ, Guardiani EA, Brewer CC, Zalewski CK, King KA, Rudy S, Van Waes C, Morgan RA, Dudley ME, Yang JC, Rosenberg SA, Kim HJ. Audiovestibular dysfunction associated with adoptive cell immunotherapy for melanoma. Otolaryngol Head Neck Surg. 2012 Oct; 147(4):744-9. PMID: 22597578.
      Citations: 10     Fields:    Translation:Humans
    255. Ahn MJ, Yang JC, Liang J, Kang JH, Xiu Q, Chen YM, Blair JM, Peng G, Linn C, Orlando M. Randomized phase II trial of first-line treatment with pemetrexed-cisplatin, followed sequentially by gefitinib or pemetrexed, in East Asian, never-smoker patients with advanced non-small cell lung cancer. Lung Cancer. 2012 Aug; 77(2):346-52. PMID: 22534669.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    256. Chung KP, Wu SG, Wu JY, Yang JC, Yu CJ, Wei PF, Shih JY, Yang PC. Clinical outcomes in non-small cell lung cancers harboring different exon 19 deletions in EGFR. Clin Cancer Res. 2012 Jun 15; 18(12):3470-7. PMID: 22510346.
      Citations: 19     Fields:    Translation:HumansCells
    257. Garg AK, Shiu AS, Yang J, Wang XS, Allen P, Brown BW, Grossman P, Frija EK, McAleer MF, Azeem S, Brown PD, Rhines LD, Chang EL. Phase 1/2 trial of single-session stereotactic body radiotherapy for previously unirradiated spinal metastases. Cancer. 2012 Oct 15; 118(20):5069-77. PMID: 22511344.
      Citations: 48     Fields:    Translation:HumansCTClinical Trials
    258. Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA. Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial. Lancet Oncol. 2012 May; 13(5):539-48. PMID: 22452895.
      Citations: 128     Fields:    Translation:HumansCTClinical Trials
    259. Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y, Heo DS, Crino L, Tan EH, Chao TY, Shahidi M, Cong XJ, Lorence RM, Yang JC. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012 May; 13(5):528-38. PMID: 22452896.
      Citations: 308     Fields:    Translation:HumansCTClinical Trials
    260. Weksberg DC, Palmer MB, Vu KN, Rebueno NC, Sharp HJ, Luo D, Yang JN, Shiu AS, Rhines LD, McAleer MF, Brown PD, Chang EL. Generalizable class solutions for treatment planning of spinal stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2012 Nov 01; 84(3):847-53. PMID: 22445000.
      Citations: 8     Fields:    Translation:Humans
    261. Wei RL, Nguyen ST, Yang JN, Wolff J, Mahajan A. Salvage craniospinal irradiation with an intensity modulated radiotherapy technique for patients with disseminated neuraxis disease. Pract Radiat Oncol. 2012 Oct-Dec; 2(4):e69-e75. PMID: 24674188.
      Citations: 3     Fields:    
    262. Wang XS, Rhines LD, Shiu AS, Yang JN, Selek U, Gning I, Liu P, Allen PK, Azeem SS, Brown PD, Sharp HJ, Weksberg DC, Cleeland CS, Chang EL. Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial. Lancet Oncol. 2012 Apr; 13(4):395-402. PMID: 22285199.
      Citations: 78     Fields:    Translation:HumansCTClinical Trials
    263. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ. CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res. 2012 Apr 01; 18(7):2039-47. PMID: 22271879.
      Citations: 180     Fields:    Translation:Humans
    264. Kuo YH, Lin ZZ, Yang YY, Shao YY, Shau WY, Kuo RN, Yang JC, Lai MS. Survival of patients with small cell lung carcinoma in Taiwan. Oncology. 2012; 82(1):19-24. PMID: 22269348.
      Citations: 7     Fields:    Translation:Humans
    265. Su KY, Chen HY, Li KC, Kuo ML, Yang JC, Chan WK, Ho BC, Chang GC, Shih JY, Yu SL, Yang PC. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012 Feb 01; 30(4):433-40. PMID: 22215752.
      Citations: 165     Fields:    Translation:Humans
    266. Tikhonova AN, Van Laethem F, Hanada K, Lu J, Pobezinsky LA, Hong C, Guinter TI, Jeurling SK, Bernhardt G, Park JH, Yang JC, Sun PD, Singer A. aß T cell receptors that do not undergo major histocompatibility complex-specific thymic selection possess antibody-like recognition specificities. Immunity. 2012 Jan 27; 36(1):79-91. PMID: 22209676.
      Citations: 46     Fields:    Translation:AnimalsCells
    267. Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22; 119(12):2709-20. PMID: 22160384.
      Citations: 556     Fields:    Translation:HumansCellsCTClinical Trials
    268. Li H, Dong L, Zhang L, Yang JN, Gillin MT, Zhu XR. Toward a better understanding of the gamma index: Investigation of parameters with a surface-based distance method. Med Phys. 2011 Dec; 38(12):6730-41. PMID: 22149855.
      Citations: 9     Fields:    
    269. Thongprasert S, Duffield E, Saijo N, Wu YL, Yang JC, Chu DT, Liao M, Chen YM, Kuo HP, Negoro S, Lam KC, Armour A, Magill P, Fukuoka M. Health-related quality-of-life in a randomized phase III first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients from Asia with advanced NSCLC (IPASS). J Thorac Oncol. 2011 Nov; 6(11):1872-80. PMID: 22011650.
      Citations: 47     Fields:    Translation:HumansCTClinical Trials
    270. Medema RH, Lin CC, Yang JC. Polo-like kinase 1 inhibitors and their potential role in anticancer therapy, with a focus on NSCLC. Clin Cancer Res. 2011 Oct 15; 17(20):6459-66. PMID: 22003073.
      Citations: 26     Fields:    Translation:Humans
    271. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, Ely G, Yang JC, Mok T. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011 Oct 07; 11:430. PMID: 21982342.
      Citations: 26     Fields:    Translation:HumansCTClinical Trials
    272. Salto-Tellez M, Tsao MS, Shih JY, Thongprasert S, Lu S, Chang GC, Au JS, Chou TY, Lee JS, Shi YK, Radzi A, Kang JH, Kim SW, Tan SY, Yang JC. Clinical and testing protocols for the analysis of epidermal growth factor receptor mutations in East Asian patients with non-small cell lung cancer: a combined clinical-molecular pathological approach. J Thorac Oncol. 2011 Oct; 6(10):1663-9. PMID: 21869714.
      Citations: 16     Fields:    Translation:Humans
    273. Yang JC. Melanoma vaccines. Cancer J. 2011 Sep-Oct; 17(5):277-82. PMID: 21952276.
      Citations: 5     Fields:    Translation:HumansAnimalsCells
    274. Tan EH, Goss GD, Salgia R, Besse B, Gandara DR, Hanna NH, Yang JC, Thertulien R, Wertheim M, Mazieres J, Hensing T, Lee C, Gupta N, Pradhan R, Qian J, Qin Q, Scappaticci FA, Ricker JL, Carlson DM, Soo RA. Phase 2 trial of Linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thorac Oncol. 2011 Aug; 6(8):1418-25. PMID: 21597387.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    275. Dalet A, Robbins PF, Stroobant V, Vigneron N, Li YF, El-Gamil M, Hanada K, Yang JC, Rosenberg SA, Van den Eynde BJ. An antigenic peptide produced by reverse splicing and double asparagine deamidation. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):E323-31. PMID: 21670269.
      Citations: 32     Fields:    Translation:HumansCells
    276. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N, Duffield EL, Rukazenkov Y, Speake G, Jiang H, Armour AA, To KF, Yang JC, Mok TS. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol. 2011 Jul 20; 29(21):2866-74. PMID: 21670455.
      Citations: 462     Fields:    Translation:HumansCTClinical Trials
    277. Langan RC, Prieto PA, Sherry RM, Zlott D, Wunderlich J, Csako G, Costello R, White DE, Rosenberg SA, Yang JC. Assessment of ovarian function after preparative chemotherapy and total body radiation for adoptive cell therapy. J Immunother. 2011 May; 34(4):397-402. PMID: 21499128.
      Citations: 3     Fields:    Translation:Humans
    278. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE, Laurencot CM, Steinberg SM, White DE, Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res. 2011 Jul 01; 17(13):4550-7. PMID: 21498393.
      Citations: 670     Fields:    Translation:HumansCellsCTClinical Trials
    279. Ascierto PA, De Maio E, Bertuzzi S, Palmieri G, Halaban R, Hendrix M, Kashani-sabet M, Ferrone S, Wang E, Cochran A, Rivoltini L, Lee PP, Fox BA, Kirkwood JM, Ullmann CD, Lehmann FF, Sznol M, Schwartzentruber DJ, Maio M, Flaherty K, Galon J, Ribas A, Yang J, Stroncek DF, Mozzillo N, Marincola FM. Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th 2010". J Transl Med. 2011 Mar 26; 9:32. PMID: 21439082.
      Citations: 6     Fields:    Translation:HumansAnimalsCells
    280. Garg AK, Wang XS, Shiu AS, Allen P, Yang J, McAleer MF, Azeem S, Rhines LD, Chang EL. Prospective evaluation of spinal reirradiation by using stereotactic body radiation therapy: The University of Texas MD Anderson Cancer Center experience. Cancer. 2011 Aug 01; 117(15):3509-16. PMID: 21319143.
      Citations: 39     Fields:    Translation:Humans
    281. Hanada K, Wang QJ, Inozume T, Yang JC. Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor. Blood. 2011 May 05; 117(18):4816-25. PMID: 21300979.
      Citations: 13     Fields:    Translation:HumansCells
    282. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, Raffeld M, Lee CC, Levy CL, Li YF, El-Gamil M, Schwarz SL, Laurencot C, Rosenberg SA. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011 Mar 01; 29(7):917-24. PMID: 21282551.
      Citations: 551     Fields:    Translation:HumansCellsCTClinical Trials
    283. Wang QJ, Hanada K, Feldman SA, Zhao Y, Inozume T, Yang JC. Development of a genetically-modified novel T-cell receptor for adoptive cell transfer against renal cell carcinoma. J Immunol Methods. 2011 Mar 07; 366(1-2):43-51. PMID: 21255579.
      Citations: 10     Fields:    Translation:HumansCells
    284. Lin CC, Yang JC. Optimal management of patients with non-small cell lung cancer and epidermal growth factor receptor mutations. Drugs. 2011 Jan 01; 71(1):79-88. PMID: 21175241.
      Citations: 2     Fields:    Translation:Humans
    285. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, Davis JL, Morgan RA, Merino MJ, Sherry RM, Hughes MS, Kammula US, Phan GQ, Lim RM, Wank SA, Restifo NP, Robbins PF, Laurencot CM, Rosenberg SA. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2011 Mar; 19(3):620-6. PMID: 21157437.
      Citations: 298     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    286. Feldman SA, Goff SL, Xu H, Black MA, Kochenderfer JN, Johnson LA, Yang JC, Wang Q, Parkhurst MR, Cross S, Morgan RA, Cornetta K, Rosenberg SA. Rapid production of clinical-grade gammaretroviral vectors in expanded surface roller bottles using a "modified" step-filtration process for clearance of packaging cells. Hum Gene Ther. 2011 Jan; 22(1):107-15. PMID: 20662590.
      Citations: 9     Fields:    Translation:AnimalsCells
    287. Inozume T, Hanada K, Wang QJ, Ahmadzadeh M, Wunderlich JR, Rosenberg SA, Yang JC. Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells. J Immunother. 2010 Nov-Dec; 33(9):956-64. PMID: 20948441.
      Citations: 56     Fields:    Translation:HumansCells
    288. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, White D, Rosenberg SA, Dudley ME, Yang JC. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010 Oct; 33(8):840-7. PMID: 20842052.
      Citations: 29     Fields:    Translation:HumansCells
    289. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010 Oct; 33(8):828-33. PMID: 20842054.
      Citations: 316     Fields:    Translation:HumansCTClinical Trials
    290. Yang JN, Ding X, Du W, Pino R. Model-based calculations of off-axis ratio of conic beams for a dedicated 6 MV radiosurgery unit. Med Phys. 2010 Oct; 37(10):5442-7. PMID: 21089780.
      Citations:    Fields:    Translation:Humans
    291. Hong JJ, Rosenberg SA, Dudley ME, Yang JC, White DE, Butman JA, Sherry RM. Successful treatment of melanoma brain metastases with adoptive cell therapy. Clin Cancer Res. 2010 Oct 01; 16(19):4892-8. PMID: 20719934.
      Citations: 60     Fields:    Translation:HumansCells
    292. Afonso N, Amponsah D, Yang J, Mendez J, Bridge P, Hays G, Baliga S, Crist K, Brennan S, Jackson M, Dulchavsky S. Adding new tools to the black bag--introduction of ultrasound into the physical diagnosis course. J Gen Intern Med. 2010 Nov; 25(11):1248-52. PMID: 20697974.
      Citations: 14     Fields:    Translation:Humans
    293. Dudley ME, Gross CA, Langhan MM, Garcia MR, Sherry RM, Yang JC, Phan GQ, Kammula US, Hughes MS, Citrin DE, Restifo NP, Wunderlich JR, Prieto PA, Hong JJ, Langan RC, Zlott DA, Morton KE, White DE, Laurencot CM, Rosenberg SA. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin Cancer Res. 2010 Dec 15; 16(24):6122-31. PMID: 20668005.
      Citations: 88     Fields:    Translation:HumansCellsCTClinical Trials
    294. Du W, Yang JN, Chang EL, Luo D, McAleer MF, Shiu A, Martel MK. A quality assurance procedure to evaluate cone-beam CT image center congruence with the radiation isocenter of a linear accelerator. J Appl Clin Med Phys. 2010 Jul 02; 11(4):3297. PMID: 21081890.
      Citations: 10     Fields:    Translation:Humans
    295. Rosenberg SA, Yang JC, Kammula US, Hughes MS, Restifo NP, Schwarz SL, Morton KE, Laurencot CM, Sherry RM. Different adjuvanticity of incomplete freund's adjuvant derived from beef or vegetable components in melanoma patients immunized with a peptide vaccine. J Immunother. 2010 Jul-Aug; 33(6):626-9. PMID: 20551834.
      Citations: 8     Fields:    Translation:HumansAnimalsCellsPHPublic HealthCTClinical Trials
    296. Du W, Yang J, Luo D, Martel M. A simple method to quantify the coincidence between portal image graticules and radiation field centers or radiation isocenter. Med Phys. 2010 May; 37(5):2256-63. PMID: 20527559.
      Citations: 12     Fields:    
    297. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010 Apr; 18(4):843-51. PMID: 20179677.
      Citations: 706     Fields:    Translation:HumansCells
    298. Harding P, Yang XP, Yang J, Shesely E, He Q, LaPointe MC. Gene expression profiling of dilated cardiomyopathy in older male EP4 knockout mice. . 2010 Feb; 298(2):H623-32. PMID: 20008274.
    299. Ripley RT, Davis JL, Klapper JA, Mathur A, Kammula U, Royal RE, Yang JC, Sherry RM, Hughes MS, Libutti SK, White DE, Steinberg SM, Dudley ME, Rosenberg SA, Avital I. Liver resection for metastatic melanoma with postoperative tumor-infiltrating lymphocyte therapy. Ann Surg Oncol. 2010 Jan; 17(1):163-70. PMID: 19777192.
      Citations: 9     Fields:    Translation:HumansCells
    300. Stein WD, Huang H, Menefee M, Edgerly M, Kotz H, Dwyer A, Yang J, Bates SE. Other paradigms: growth rate constants and tumor burden determined using computed tomography data correlate strongly with the overall survival of patients with renal cell carcinoma. Cancer J. 2009 Sep-Oct; 15(5):441-7. PMID: 19826366.
      Citations: 7     Fields:    Translation:Humans
    301. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, Kammula US, Royal RE, Sherry RM, Wunderlich JR, Lee CC, Restifo NP, Schwarz SL, Cogdill AP, Bishop RJ, Kim H, Brewer CC, Rudy SF, VanWaes C, Davis JL, Mathur A, Ripley RT, Nathan DA, Laurencot CM, Rosenberg SA. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood. 2009 Jul 16; 114(3):535-46. PMID: 19451549.
      Citations: 488     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    302. Yeh S, Karne NK, Kerkar SP, Heller CK, Palmer DC, Johnson LA, Li Z, Bishop RJ, Wong WT, Sherry RM, Yang JC, Dudley ME, Restifo NP, Rosenberg SA, Nussenblatt RB. Ocular and systemic autoimmunity after successful tumor-infiltrating lymphocyte immunotherapy for recurrent, metastatic melanoma. Ophthalmology. 2009 May; 116(5):981-989.e1. PMID: 19410956.
      Citations: 31     Fields:    Translation:HumansCells
    303. Inozume T, Hanada K, Wang QJ, Yang JC. IL-17 secreted by tumor reactive T cells induces IL-8 release by human renal cancer cells. J Immunother. 2009 Feb-Mar; 32(2):109-17. PMID: 19238009.
      Citations: 14     Fields:    Translation:HumansCells
    304. Du W, Yang J. A robust Hough transform algorithm for determining the radiation centers of circular and rectangular fields with subpixel accuracy. Phys Med Biol. 2009 Feb 07; 54(3):555-67. PMID: 19124954.
      Citations: 6     Fields:    
    305. Yang JN, Pino R. Analytical calculation of central-axis dosimetric data for a dedicated 6-MV radiosurgery linear accelerator. Med Phys. 2008 Oct; 35(10):4333-41. PMID: 18975679.
      Citations:    Fields:    Translation:HumansPHPublic Health
    306. Stein WD, Yang J, Bates SE, Fojo T. Bevacizumab reduces the growth rate constants of renal carcinomas: a novel algorithm suggests early discontinuation of bevacizumab resulted in a lack of survival advantage. Oncologist. 2008 Oct; 13(10):1055-62. PMID: 18827177.
      Citations: 20     Fields:    Translation:HumansCTClinical Trials
    307. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF, Wunderlich J, Restifo NP, Thomasian A, Downey SG, Smith FO, Klapper J, Morton K, Laurencot C, White DE, Rosenberg SA. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol. 2008 Nov 10; 26(32):5233-9. PMID: 18809613.
      Citations: 518     Fields:    Translation:HumansCellsCTClinical Trials
    308. Wang QJ, Hanada K, Yang JC. Characterization of a novel nonclassical T cell clone with broad reactivity against human renal cell carcinomas. J Immunol. 2008 Sep 15; 181(6):3769-76. PMID: 18768829.
      Citations: 6     Fields:    Translation:HumansCells
    309. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Restifo NP, Levy CL, White DE, Steinberg SM, Rosenberg SA. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008 Sep 01; 14(17):5610-8. PMID: 18765555.
      Citations: 66     Fields:    Translation:Humans
    310. Klapper JA, Downey SG, Smith FO, Yang JC, Hughes MS, Kammula US, Sherry RM, Royal RE, Steinberg SM, Rosenberg S. High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer. 2008 Jul 15; 113(2):293-301. PMID: 18457330.
      Citations: 114     Fields:    Translation:Humans
    311. Yang JC. Vitespen: a vaccine for renal cancer? Lancet. 2008 Jul 12; 372(9633):92-3. PMID: 18602687.
      Citations: 6     Fields:    Translation:Humans
    312. Yan H, Zhu G, Yang J, Lu M, Ajlouni M, Kim JH, Yin FF. The investigation on the location effect of external markers in respiratory-gated radiotherapy. J Appl Clin Med Phys. 2008 Apr 16; 9(2):57-68. PMID: 18714280.
      Citations: 13     Fields:    Translation:Humans
    313. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008 Apr; 8(4):299-308. PMID: 18354418.
      Citations: 544     Fields:    Translation:Humans
    314. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, Yellin M, Nichol G, White DE, Steinberg SM, Rosenberg SA. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6681-8. PMID: 17982122.
      Citations: 181     Fields:    Translation:Humans
    315. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, Lowy I, White DE, Rosenberg SA. Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother. 2007 Nov-Dec; 30(8):825-30. PMID: 18049334.
      Citations: 211     Fields:    Translation:HumansCTClinical Trials
    316. Ciangaru G, Yang JN, Oliver PJ, Bues M, Zhu M, Nakagawa F, Chiba H, Nakamura S, Yoshino H, Umezawa M, Smith AR. Verification procedure for isocentric alignment of proton beams. J Appl Clin Med Phys. 2007 Oct 24; 8(4):65-75. PMID: 18449154.
      Citations: 7     Fields:    
    317. Yang JC, Childs R. Immunotherapy for renal cell cancer. J Clin Oncol. 2006 Dec 10; 24(35):5576-83. PMID: 17158543.
      Citations: 25     Fields:    Translation:HumansCells
    318. Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006 Oct 15; 12(20 Pt 1):6106-15. PMID: 17062687.
      Citations: 379     Fields:    Translation:HumansCellsCTClinical Trials
    319. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 06; 314(5796):126-9. PMID: 16946036.
      Citations: 889     Fields:    Translation:HumansCellsCTClinical Trials
    320. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, Allen T, Mavroukakis SA, Attia P, Rosenberg SA. Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. J Immunother. 2006 Jul-Aug; 29(4):455-63. PMID: 16799341.
      Citations: 67     Fields:    Translation:HumansCTClinical Trials
    321. Beck KE, Blansfield JA, Tran KQ, Feldman AL, Hughes MS, Royal RE, Kammula US, Topalian SL, Sherry RM, Kleiner D, Quezado M, Lowy I, Yellin M, Rosenberg SA, Yang JC. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol. 2006 May 20; 24(15):2283-9. PMID: 16710025.
      Citations: 214     Fields:    Translation:Humans
    322. Yang JC, Abad J, Sherry R. Treatment of oligometastases after successful immunotherapy. Semin Radiat Oncol. 2006 Apr; 16(2):131-5. PMID: 16564448.
      Citations: 6     Fields:    Translation:Humans
    323. Rosenberg SA, Sherry RM, Morton KE, Yang JC, Topalian SL, Royal RE, Kammula US, Restifo NP, Hughes MS, Schwarz SL, Ngo LT, Mavroukakis SA, White DE. Altered CD8(+) T-cell responses when immunizing with multiepitope peptide vaccines. J Immunother. 2006 Mar-Apr; 29(2):224-31. PMID: 16531823.
      Citations: 13     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    324. Blansfield JA, Beck KE, Tran K, Yang JC, Hughes MS, Kammula US, Royal RE, Topalian SL, Haworth LR, Levy C, Rosenberg SA, Sherry RM. Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. J Immunother. 2005 Nov-Dec; 28(6):593-8. PMID: 16224277.
      Citations: 97     Fields:    Translation:HumansCTClinical Trials
    325. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, Royal RE, Kammula U, Restifo NP, Hughes MS, Schwartzentruber D, Berman DM, Schwarz SL, Ngo LT, Mavroukakis SA, White DE, Steinberg SM. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8+ T cells in patients with melanoma. J Immunol. 2005 Nov 01; 175(9):6169-76. PMID: 16237114.
      Citations: 160     Fields:    Translation:HumansCellsPHPublic Health
    326. Wang QJ, Hanada K, Perry-Lalley D, Bettinotti MP, Karpova T, Khong HT, Yang JC. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor. J Immunother. 2005 Nov-Dec; 28(6):551-9. PMID: 16224272.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    327. Maker AV, Phan GQ, Attia P, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Haworth LR, Levy C, Kleiner D, Mavroukakis SA, Yellin M, Rosenberg SA. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study. Ann Surg Oncol. 2005 Dec; 12(12):1005-16. PMID: 16283570.
      Citations: 142     Fields:    Translation:HumansCTClinical Trials
    328. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Restifo NP, Haworth LR, Levy C, Mavroukakis SA, Nichol G, Yellin MJ, Rosenberg SA. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005 Sep 01; 23(25):6043-53. PMID: 16087944.
      Citations: 263     Fields:    Translation:HumansCTClinical Trials
    329. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA, Rogers LJ, Gracia GJ, Jones SA, Mangiameli DP, Pelletier MM, Gea-Banacloche J, Robinson MR, Berman DM, Filie AC, Abati A, Rosenberg SA. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol. 2005 Apr 01; 23(10):2346-57. PMID: 15800326.
      Citations: 545     Fields:    Translation:HumansCellsCTClinical Trials
    330. Hanada K, Yang JC. Novel biochemistry: post-translational protein splicing and other lessons from the school of antigen processing. J Mol Med (Berl). 2005 Jun; 83(6):420-8. PMID: 15759099.
      Citations: 1     Fields:    Translation:HumansAnimalsCells
    331. Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP. Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J Immunol. 2004 Dec 15; 173(12):7209-16. PMID: 15585842.
      Citations: 46     Fields:    Translation:AnimalsCells
    332. Khong HT, Yang JC, Topalian SL, Sherry RM, Mavroukakis SA, White DE, Rosenberg SA. Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen. J Immunother. 2004 Nov-Dec; 27(6):472-7. PMID: 15534491.
      Citations: 19     Fields:    Translation:HumansCellsCTClinical Trials
    333. Robinson MR, Chan CC, Yang JC, Rubin BI, Gracia GJ, Sen HN, Csaky KG, Rosenberg SA. Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis. J Immunother. 2004 Nov-Dec; 27(6):478-9. PMID: 15534492.
      Citations: 39     Fields:    Translation:HumansCells
    334. Atkins MB, Avigan DE, Bukowski RM, Childs RW, Dutcher JP, Eisen TG, Figlin RA, Finke JH, Flanigan RC, George DJ, Goldberg SN, Gordon MS, Iliopoulos O, Kaelin WG, Linehan WM, Lipton A, Motzer RJ, Novick AC, Stadler WM, Teh BT, Yang JC, King L. Innovations and challenges in renal cancer: consensus statement from the first international conference. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6277S-81S. PMID: 15448017.
      Citations: 7     Fields:    Translation:Humans
    335. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res. 2004 Sep 15; 10(18 Pt 2):6367S-70S. PMID: 15448032.
      Citations: 27     Fields:    Translation:HumansCTClinical Trials
    336. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med. 2004 Sep; 10(9):909-15. PMID: 15340416.
      Citations: 828     Fields:    Translation:HumansCells
    337. Elaraj DM, White DE, Steinberg SM, Haworth L, Rosenberg SA, Yang JC. A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma. J Immunother. 2004 Jul-Aug; 27(4):259-64. PMID: 15235386.
      Citations: 11     Fields:    Translation:HumansCTClinical Trials
    338. Hanada K, Yewdell JW, Yang JC. Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature. 2004 Jan 15; 427(6971):252-6. PMID: 14724640.
      Citations: 70     Fields:    Translation:HumansAnimalsCells
    339. Rosenberg SA, Yang JC, Robbins PF, Wunderlich JR, Hwu P, Sherry RM, Schwartzentruber DJ, Topalian SL, Restifo NP, Filie A, Chang R, Dudley ME. Cell transfer therapy for cancer: lessons from sequential treatments of a patient with metastatic melanoma. J Immunother. 2003 Sep-Oct; 26(5):385-93. PMID: 12973027.
      Citations: 23     Fields:    Translation:HumansCells
    340. Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003 Aug 15; 21(16):3127-32. PMID: 12915604.
      Citations: 169     Fields:    Translation:HumansCTClinical Trials
    341. Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Topalian SL, Sherry RM, Restifo NP, Wunderlich JR, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, Gritz L, Panicali DL, White DE. Recombinant fowlpox viruses encoding the anchor-modified gp100 melanoma antigen can generate antitumor immune responses in patients with metastatic melanoma. Clin Cancer Res. 2003 Aug 01; 9(8):2973-80. PMID: 12912944.
      Citations: 30     Fields:    Translation:HumansCellsCTClinical Trials
    342. Yang JC, Haworth L, Sherry RM, Hwu P, Schwartzentruber DJ, Topalian SL, Steinberg SM, Chen HX, Rosenberg SA. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003 Jul 31; 349(5):427-34. PMID: 12890841.
      Citations: 629     Fields:    Translation:HumansCTClinical Trials
    343. Phan GQ, Touloukian CE, Yang JC, Restifo NP, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens. J Immunother. 2003 Jul-Aug; 26(4):349-56. PMID: 12843797.
      Citations: 34     Fields:    Translation:HumansCellsCTClinical Trials
    344. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, Duray PH, Steinberg SM, Allison JP, Davis TA, Rosenberg SA. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A. 2003 Jul 08; 100(14):8372-7. PMID: 12826605.
      Citations: 435     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    345. Rosenberg SA, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, Morton KE, Mavroukakis SA, White DE. Inability to immunize patients with metastatic melanoma using plasmid DNA encoding the gp100 melanoma-melanocyte antigen. Hum Gene Ther. 2003 May 20; 14(8):709-14. PMID: 12804135.
      Citations: 25     Fields:    Translation:HumansCellsCTClinical Trials
    346. Barrett JC, Bennett LM, Fleming LK, Linehan WM, Liotta LA, Rosenberg SA, Petricoin EF, Staudt LM, Thompson TE, Yang JC. Linking laboratory and clinical research: the development of molecularly targeted therapeutics inside the national cancer institute center for cancer research. Clin Adv Hematol Oncol. 2003 May; 1(5):302-6. PMID: 16224427.
      Citations: 1     Fields:    Translation:Humans
    347. O'Reilly F, Feldman E, Yang J, Hwu P, Turner ML. Recurring cutaneous eruption in a patient with metastatic renal cell carcinoma being treated with high-dose interleukin 2. J Am Acad Dermatol. 2003 Apr; 48(4):602-4. PMID: 12664026.
      Citations:    Fields:    Translation:Humans
    348. Freedman NM, Sundaram SK, Kurdziel K, Carrasquillo JA, Whatley M, Carson JM, Sellers D, Libutti SK, Yang JC, Bacharach SL. Comparison of SUV and Patlak slope for monitoring of cancer therapy using serial PET scans. Eur J Nucl Med Mol Imaging. 2003 Jan; 30(1):46-53. PMID: 12483409.
      Citations: 28     Fields:    Translation:Humans
    349. Feldman AL, Alexander HR, Yang JC, Linehan WM, Eyler RA, Miller MS, Steinberg SM, Libutti SK. Prospective analysis of circulating endostatin levels in patients with renal cell carcinoma. Cancer. 2002 Oct 15; 95(8):1637-43. PMID: 12365010.
      Citations: 19     Fields:    Translation:Humans
    350. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry R, Restifo NP, Hubicki AM, Robinson MR, Raffeld M, Duray P, Seipp CA, Rogers-Freezer L, Morton KE, Mavroukakis SA, White DE, Rosenberg SA. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002 Oct 25; 298(5594):850-4. PMID: 12242449.
      Citations: 855     Fields:    Translation:HumansCellsCTClinical Trials
    351. Wang HY, Fu T, Wang G, Zeng G, Perry-Lalley DM, Yang JC, Restifo NP, Hwu P, Wang RF. Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells. J Clin Invest. 2002 Jun; 109(11):1463-70. PMID: 12045260.
      Citations: 23     Fields:    Translation:AnimalsCells
    352. Dudley ME, Wunderlich JR, Yang JC, Hwu P, Schwartzentruber DJ, Topalian SL, Sherry RM, Marincola FM, Leitman SF, Seipp CA, Rogers-Freezer L, Morton KE, Nahvi A, Mavroukakis SA, White DE, Rosenberg SA. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002 May-Jun; 25(3):243-51. PMID: 12000866.
      Citations: 107     Fields:    Translation:HumansCellsCTClinical Trials
    353. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, Sherry RM, Topalian SL, Yang JC, Stock F, Freezer LJ, Morton KE, Seipp C, Haworth L, Mavroukakis S, White D, MacDonald S, Mao J, Sznol M, Rosenberg SA. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):142-52. PMID: 11773163.
      Citations: 170     Fields:    Translation:HumansCellsCTClinical Trials
    354. Guirguis LM, Yang JC, White DE, Steinberg SM, Liewehr DJ, Rosenberg SA, Schwartzentruber DJ. Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases. J Immunother. 2002 Jan-Feb; 25(1):82-7. PMID: 11924913.
      Citations: 25     Fields:    Translation:Humans
    355. Yang JN, Mackie TR, Reckwerdt P, Deasy JO, Thomadsen BR. An investigation of tomotherapy beam delivery. Med Phys. 1997 Mar; 24(3):425-36. PMID: 9089594.
      Citations: 24     Fields:    Translation:Humans
    356. Mackie TR, Holmes T, Swerdloff S, Reckwerdt P, Deasy JO, Yang J, Paliwal B, Kinsella T. Tomotherapy: a new concept for the delivery of dynamic conformal radiotherapy. Med Phys. 1993 Nov-Dec; 20(6):1709-19. PMID: 8309444.
      Citations: 153     Fields:    Translation:Humans
    357. Yang JN, Murphy AD, Madsen EL, Zagzebski JA, Gilchrist KW, Frank GR, Macdonald MC, Millard CA, Faraggi A, Jaramillo CA, et al. A method for in vitro mapping of ultrasonic speed and density in breast tissue. Ultrason Imaging. 1991 Jan; 13(1):91-109. PMID: 1998250.
      Citations: 2     Fields:    Translation:Humans
    358. Verification procedure for isocentric alignment of proton beams. Journal of Applied Clinical Medical Physics. 8:65-75.
    359. Tomotherapy. International Journal of Imaging Systems and Technology. 6:43-55.
    360. Improved setup and positioning accuracy using a three-point customized cushion/mask/bite-block immobilization system for stereotactic reirradiation of head and neck cancer. Journal of Applied Clinical Medical Physics. 17:180-189.
    361. Salvage craniospinal irradiation with an intensity modulated radiotherapy technique for patients with disseminated neuraxis disease. Practical Radiation Oncology. 2.
    362. Investigation of 3D dosimetry for an anthropomorphic spine phantom. Journal of Physics: Conference Series. 444.
    363. Single-fraction versus multifraction spinal stereotactic radiosurgery for spinal metastases from renal cell carcinoma. Journal of Neurosurgery: Spine. 24:829-836.
    364. A quality assurance procedure to evaluate cone-beam CT image center congruence with the radiation isocenter of a linear accelerator. Journal of Applied Clinical Medical Physics. 11:15-26.
    365. Gamma Knife Stereotactic Radiosurgery for Brain Metastases Using Only 3 Pins. Neurosurgery.
    YANG's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (853)
    Co-Authors (55)
    Similar People (60)
    Same Department Expand Description